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ABSTRACT 
 
 
Effect of Prebiotic, Probiotic, and Enzyme Supplementation on Gut Fermentation, Markers of 
Inflammation and Immune Response in Individuals with GI Symptoms 
 
 
by 
 
Kaitlyn M. Webb  
 
 
Current practices support the use of probiotic and prebiotic supplementation to improve chronic 
gastrointestinal distress (GID). The aim of this study was to determine the tolerance and benefits 
of GlutenShield (GS), a prebiotic, probiotic, and enzyme supplement, on adults with GID. 
Subjects (n=20) took either GS or the placebo for 30 days and completed a pre-treatment FFQ as 
well as a pre- and post-treatment GID questionnaire, blood draw, and stool sample. Participants 
consumed more total and saturated fat, and less fiber and whole grains compared to the 
recommended intake. A significant reduction in IgG2 was observed in the GS group (p=0.008) as 
well as a significant reduction in self-reported bloating (p=0.038) with no change observed to 
cytokines or SCFAs (p>0.05). GS was well tolerated and perceived to be beneficial; however, 
further research is needed to identify the specific population of GID patients who could most 
benefit from GS supplementation. 
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CHAPTER 1 
INTRODUCTION 
Probiotics and prebiotics are common nutrition supplements consumed by individuals to 
enhance immune function, attenuate gastrointestinal upset, improve mood and provide a host of 
other benefits. Currently, probiotic and prebiotic supplements are recommended by physicians, 
dietitians, and other healthcare providers to mitigate symptoms/side effects associated with 
certain disease states and medications and are also supplemented to improve quality of life.  The 
purpose of this research is to identify if there is a relationship between GlutenShield, a 
combination prebiotic, probiotic, and enzyme supplement, and the gut environment of 
individuals with gastrointestinal upset. The secondary purpose is to understand the effects that 
probiotics, prebiotics, and enzymes in relation to the claims currently being supported. In an 
article published by the Academy of Nutrition and Dietetics on eatright.org, Registered Dietitian 
Taylor Wolfram claims that probiotics “are linked to promoting the growth of helpful bacteria in 
the gut,” “may boost immunity and overall health, especially GI health,” and “bottom line: At a 
minimum, prebiotics and probiotics are keys for good gut health, which affects many other areas 
of the body.”1 Through this research we provide complete picture of the diet, lifestyle, 
fermentation, and inflammatory profile of a group of individuals with gastrointestinal upset. 
From there we investigate the impact that targeted probiotic, prebiotic, and enzyme 
supplementation has on gastrointestinal symptoms, mood states, fermentation, and markers of 
immunity and inflammation. Research Objectives are detailed below: 
1.  To determine if there is a correlation between typical dietary intake and initial fecal short 
chain fatty acid concentration, markers of inflammation, and predominant gut microbial 
population. 
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2. To determine if pre-/probiotic/enzyme supplementation affects short chain fatty acid 
production in the gut as evidenced by short chain fatty acid concentration in fecal matter 
to improve digestion, absorption, and bowel function. 
3. To determine whether pre-/probiotic/enzyme supplementation will improve serum 
markers of inflammation, including GM-CSF, IFN-gamma, IL-2, IL-4, IL-6, IL-8, IL-10 
and TNF-alpha and IgA and IgG. 
4. To determine whether pre-/probiotic/enzyme supplementation will create an 
improvement in psychosocial measures of self (Profile of Mood States 2nd Edition 
survey). 
5. To determine whether pre-/probiotic/enzyme supplementation alters the predominant gut 
microbial population in feces.  
6. To determine whether pre-/probiotic/enzyme supplementation alters the concentration of 
microbes in feces. 
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CHAPTER 2 
REVIEW OF LITERATURE 
Gastrointestinal Upset 
Epidemiology 
Symptoms of gastrointestinal (GI) upset include abdominal pain, heartburn, acid 
regurgitation, bloating, nausea and vomiting, abdominal distension, eructation, increased gas, 
decreased passage of stools, increased passage of stools, loose stools, hard stools, urgent need for 
defecation, and feeling of incomplete evacuation.2 Chronic GI symptoms unexplained by 
structural or biochemical abnormalities are common in the primary care setting; however, 
epidemiological data concerning general GI symptoms is generally unavailable for the United 
States/ North America.3 In the general global population, the occurrence of chronic GI symptoms 
is estimated to be 5.3-20.4%.3 Further, according to Peery et al, abdominal pain resulted in 
8,863,568 outpatient visits in 2009, while constipation resulted in 3,980,438 visits and diarrhea 
resulted in 2,402,350 visits in the United States.4 In an effort to characterize the prevalence and 
defining characteristics of GI upset, epidemiological data on constipation and diarrhea is 
discussed below. 
According to a systematic review conducted by Higgins et al, the prevalence of 
constipation ranges from 1.9% to 27.2% in North America with an average percentage of 14.8. 
Studies that relied on self-reported constipation documented a prevalence of 27.2 per 100 
individuals; whereas, studies that evaluated constipation using the Rome Criteria estimated a 
lower prevalence of 14.9-16.7 per 100 individuals.5 Despite the differences in criteria to evaluate 
and define constipation, studies consistently reported a higher ratio of constipation in females 
compared to males at 2.2:1.5 Higgins et al’s systematic review indicated that incidences of 
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constipation gradually increased after age 50 and dramatically increased after age 70.5 Very few 
studies evaluate the effects of constipation on perceived quality of life and psychosocial 
measures. In a survey evaluating health-related quality of life, researchers discovered a 
significant difference in health related quality of life in individuals with constipation compared 
to those without constipation.6 Additionally, women reported a greater impaired quality of life 
compared to men.6   
Based on the 2009-2010 National Health and Nutrition Examination Survey (NHANES) 
bowel health questionnaire, the prevalence of chronic diarrhea in adults in the United States, 
excluding inflammatory bowel disease and celiac disease, is 6.6%.7 Similar to constipation, the 
incidence of chronic diarrhea is 1.4 times greater in females compared to males (p=0.004).7 Also, 
individuals with a BMI 30 and individuals over the age of 70 had a higher prevalence of 
diarrhea compared to individuals with a BMI 29 and individuals between the ages of 20-29 
(p0.005).7 Buono et al, using the 2012 National Health and Wellness Survey, found that 
individuals with chronic diarrhea (irritable bowel syndrome- diarrhea) have a significantly lower 
quality of life score (p<0.001), have higher rates of absenteeism from work (p<0.001), have 
lower work productivity (p<0.001), and have higher rates of physical activity impairment 
(p<0.001).8 
Diet 
 Research on dietary intake and distribution of calories among individuals with GI 
symptoms is limited. One such study compared the dietary intake of 99 individuals with 
functional gastrointestinal disorders (FGIDs) to 119 individuals without symptoms (controls).9 
Using the Bowel Disease Questionnaire to evaluate GI symptoms and the Harvard Food 
Frequency Questionnaire to evaluate usual dietary intake over a given week, Saito et al found 
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that consumption of wheat-containing foods, lactose-containing foods, caffeinated drinks, 
fructose-sweetened beverages, and alcoholic beverages was similar between both groups 
(p>0.05).9 Further, mean caloric, carbohydrate, protein, fat, and vitamin intake was similar 
between groups (p>0.05).9 As a percentage of total calories, individuals with FGIDs consumed a 
higher percentage of calories from fat, saturated fat, and monounsaturated fat compared to 
controls (p<0.05); however, there was no difference in the percentage of calories from 
polyunsaturated fats (p>0.05).9 When assessing consumption of bioactive substances, there were 
no differences in the amount of serotonin-containing or tryptophan-containing foods (p>0.05).9 
Consumption of epinephrine-containing foods (chocolate, nuts, bananas, oranges, and raisins) 
was slightly higher in FGID individuals compared to controls (57% vs 45%); however, the 
difference was not statistically significant (p=0.10).9 Although limited research is available, the 
results of this study suggest that the diet of individuals with GI symptoms is similar to the diet of 
individuals without GI symptoms. Interestingly, individuals with FGIDs had similar 
consumption of foods that are commonly thought to cause GI upset (i.e. lactose, wheat, and 
fructose).9 
 In contrast to the above study, Torres et al evaluated the diets of 1,870 individuals 
formally diagnosed with irritable bowel syndrome (IBS) compared to 34,578 healthy individuals 
(controls) using three 24-hour recalls that were administered randomly over a 6-month period.10 
IBS is a gastrointestinal disorder characterized by abdominal pain and altered bowel habits 
(diarrhea, constipation, or mixed).10 Individuals with IBS had a lower consumption of milk 
(p<0.0001), yogurt (p=0.001), and fruits (p<0.001) compared to controls.10 Individuals with IBS 
had a higher total caloric intake compared to controls (p<0.001) and IBS subjects were more 
likely to consume the recommended dietary fiber intake (25g/day) compared to control subjects 
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(p=0.07).10 It is generally assumed that there is a positive correlation between certain dietary 
habits and gastrointestinal upset, however, as the above research studies suggest, there is a high 
level of heterogeneity in the specific dietary factors that contribute to GI upset.10 Other factors, 
such as the human gut microbiome, can influence the GI tract and the presence of GI symptoms. 
The Human Gut Microbiome 
Schippa et al. compares the human gut microbiome to the intricacy of a fingerprint. 
Similar to a fingerprint, the colonic microbiome is complex and varies from person to person.11 
The colonic microbiota can contain over 100 different bacterial phyla; further, the composition 
of the microbiota changes based on one’s diet, weight status, environment, geographical location, 
and health status (i.e. inflammatory and disease status). Understanding these factors allows 
researchers to better understand the components of a symbiotic, or healthy, gut microbiome as 
well as the components of a dysbiotic, or imbalanced, microbiome.  
Core Microbiome 
Research shows that the microbiome can be generalized to an extent. For example, 
Backhed et al found that the human gut microbiome is dominated by two phyla- Bacteroidetes 
and Firmicutes.12 Zupancic et al supported the predominance of Bacteroidetes and Firmicutes in 
the colonic microbiome and also found a significant correlation between the Bacteroidetes: 
Firmicutes ratio and age and sex-adjusted BMI (p=0.04).13 That being said, Zupancic et al 
observed significant differences in the concentration of both dominant and rare genera in 95% 
of subjects.13 By sequencing 16S rDNA, Schippa et al supported Zupancic’s research. Schippa et 
al found that the majority of bacterial species detected in the gut belong to the Bacteroidetes and 
Firmicutes phyla.11 Mariot et al observed an average ratio of 10.9 of Firmicutes to Bacteroidetes 
in the fecal microbiota of adults.14 The ratio of Firmicutes to Bacteroidetes is thought to be an 
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indicator of gut microbial health.15 Typically, Firmicutes represent 60-80% of the total bacteria 
within the gut while Bacteroidetes represent 15-30% of the total bacteria within the gut.15   
According to Harmsen et al and Mariat et al, anaerobic fecal bacterial can also be divided 
into two groups by genus: dominant and subdominant.14,16 Dominant anaerobic fecal bacteria, 
which are >109 coliform forming units (CFUs)/gram, include Bacteroides, Eubacterium, 
Bifidobacterium, Peptostreptococcus, Ruminococcus, Clostridium and Propionibacterium.14,16 
Subdominant anaerobic fecal bacteria, which are <109 CFUs/gram, include Streptococcus, 
Enterococcus, Lactobacillus, Fusobacterium, Desulfovibrio and Methanobrevibacter as well as 
certain bacteria from Enterobacteriaceae family, particularly Escherichia coli.14,16 
Despite the diversity of bacterial species, Schippa et al and Turnbaugh et al argue for a 
common core gut microbiome, or set of functions that are shared by the majority of gut microbial 
genes.11,17 Functions of these core genes include the synthesis of short-chain fatty acids (SCFAs), 
amino acids and vitamins, as well as the degradation of polysaccharides.11,17  
Microbial Profile of GI Upset 
Physiological etiologies that may lead to GI symptoms include abnormal GI motility, 
visceral hypersensitivity (heightened pain within viscera), immune dysregulation, inflammation, 
mucosal barrier dysfunction, alterations in the gut microbiome, dietary intake and variety, 
maldigestion or malabsorption of nutrients, as well as the amplification or disruption of the gut-
brain axis.18 For the purpose of this review, GI symptoms are discussed in relation to the colonic 
microbiome and in relation to dietary intake. Alterations of the gut microbiome may not only 
contribute to GI upset, but GI symptoms may also be a reflection of an altered microbiome.  
In a cross-sectional study, Zhu et al found that children with constipation had a 
significantly different microbial profile compared to children without constipation. Children with 
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constipation had a significantly higher proportion of several different Firmicutes.19 Mancabelli et 
al similarly found that adults with functional constipation (FC), defined as having three or less 
bowel movements per week, have a different fecal microbiota composition compared to healthy 
subjects (HS).20 At a phyla level, FC and HS participants both had an predominance of 
Bacteroidetes and Firmicutes; however, the abundance differed between groups. At a genus 
level, FC participants exhibited increased average relative abundance of Bacteroides (34.25%) , 
Faecalibacterium (6.85%), Alistipes (6.48%), and Lachnospira (4.44%) bacteria.20 HS subjects 
also had increased relative abundance of Bacteroides (45.23%) and Alistipes (5.34%). The 
researchers did not find a specific microbial biomarker associated with functional constipation.20 
That being said, HS participants had a higher concentration of Bacteroides (p=0.0004), 
Roseburia (p=0.006), and Coprococcus (p<0.01), while FC subjects had higher concentrations of 
Faecalibacterium (p=0.0001) and other genera of the Ruminococcacae family.20 
Mancabelli et al then selected 10 participants, 5 FC and 5 HS, and performed Ilumina 
shotgun sequencing.20 The data collected from shotgun sequencing the samples was used to 
compare microbial pathways between FC and HS subjects using the MetaCyc database. The 
researchers found a significant difference in 629 metabolic pathways. HS individuals had a 
higher number of genes associated with carbohydrate and fatty acid metabolism (p<0.05) 
compared to FC subjects. These pathways influence the production of SCFAs and may provide a 
defense for the etiology of functional constipation based on one’s gut microbiome. In contrast, 
FC subjects had a higher abundance of methanogenic pathway genes, meaning FC subjects have 
a predicted higher capacity to produce hydrogen compared to HS subjects (p=0.05).20 
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Individuals with diarrhea also display an altered gut microbial distribution. Samb-Ba et al 
found that adults with diarrhea had a significantly higher number of bacterial species per stool 
sample compared to adults without diarrhea; however, the individuals with diarrhea had lower 
proportions of Bacteroides ssp. (including Bacteroidetes vulgatis) in comparison.21 This is 
supported by Chang et al in a study that evaluated the fecal microbiota of adults with Clostridium 
difficile associated diarrhea through analysis of 16S rRNA gene sequences.22 Chang et al found 
that the majority of gene sequences from the control subjects were from the Bacteroidetes and 
Firmicutes phyla; however, individuals with C. difficile, an opportunistic pathogen, had an 
altered distribution of the 16S phylotypes, indicating a deviation from what is recognized as the 
“normal” microbiome.22 
Nutrients and the Gut Microbiome 
The composition of the human gut microbiota is strongly influenced by the composition 
of one’s diet. Roughly eight hours after consuming a meal, undigested chyme, primarily 
indigestible polysaccharides, resistant proteins, water and electrolytes as well as endogenous 
mucins and enzymes, enter the large intestine for further digestion and absorption.23 Within the 
colon, water and electrolytes are rapidly absorbed, microbial fermentation occurs, and feces are 
formed and stored. A diverse microbial community known as the gut microbiome, works to 
salvage energy and absorbable nutrients, feed the intestinal epithelial cells, and protect the host 
against invasion by pathogenic organisms.23 The composition of the gut environment directly 
affects colonic transit time, pH, osmolarity, and gas production.24 
Carbohydrates are the major substrates that influence the colonic microbiome. While the 
majority of carbohydrate digestion and absorption occurs in the small intestine, certain 
carbohydrates bypass the small intestine and enter the large intestine undigested. These 
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carbohydrates include plant cell wall polysaccharides (cellulose, arabinoxylan, xyloglucan, b-
glucan, mannan, pectins and lignin), resistant starch, inulin, fructo-oligosaccharides, simple 
sugars and sugar alcohols.24 Some plant cell-wall polysaccharides, such as cellulose and lignin, 
are only partially digested in the large intestine, while hemicelluloses and pectins undergo more 
complete breakdown by colonic bacteria.23 As an example, Dongowaski et al found that cultures 
of Bacteroides thetaiotaomicron isolated from human fecal flora first degraded pectin to 
oligogalacturonic acids and then completely fermented the oligogalacturonic acids to SCFAs and 
gases within 24 hours in vitro.25 
Fructans (i.e. inulin and fructo-oligosaccharides (FOSs)), found naturally in certain fruits 
(bananas), vegetables (garlic, onions, artichokes), and grains (wheat, barley), have been shown to 
stimulate the growth of beneficial bacteria in the colon.26 As such, inulin and FOSs, are 
commonly referred to as prebiotics. Research shows that different prebiotics have varying 
capabilities to stimulate the growth of bacteria within the gut. Scott et al demonstrated that short-
chain FOS were able to stimulate the growth of several Firmicutes, Actinomycetes, and 
Bacteroidetes, including Roseburia, Bifidobacterium, and Bacteroides species; however, many 
bacteria were unable to utilize long-chain FOS (inulin) for growth.26 
Unabsorbed sugars and sugar alcohols can also be used as substrates for fermentation in 
the large intestine. In a randomized-crossover study conducted by Vogt et al human subjects 
ingested 25g of L-rhamnose, lactulose, or d-glucose per day for 28 days.27 Results from the study 
showed that L-rhamnose significantly increased serum propionate when compared to lactulose 
(p<0.05), while lactulose supplementation raised the serum acetate: propionate ratio (p<0.005).27 
Both results indicate fermentation of 6-carbon sugars; however, the specific microbes 
responsible for fermentation were not assessed.27 Different phyla, species, and strains of bacteria 
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ferment different carbohydrate sources, and, as a result, produce different end-products. 
Identifying typical carbohydrate sources through use of food recalls can allow researchers to 
identify the amount and types end-products produced to potentially exert beneficial effects to the 
host. 
Short Chain Fatty Acids 
Production and Absorption 
Short-chain fatty acids (SCFAs) are the primary end-products of anaerobic bacterial 
fermentation in the colon. The three major SCFAs – acetic acid (C2), propionic acid (C3), and 
butyric acid (C4) (structures shown in Table 1) – are produced via carbohydrate fermentation 
and represent 90-95% of the SCFAs produced in the large intestine.28 Acetate, propionate, and 
butyrate are typically produced in a 3:1:1 ratio.28 Select branched chain fatty acids are also 
produced via proteolytic breakdown of valine, leucine, and isoleucine.     
There is no single metabolic pathway for the production of SCFAs, rather several 
pathways are used depending on the colonic microbiota composition, the substrates available for 
fermentation, and other environmental conditions (i.e. colonic pH and level of CO2 production). 
These pathways are important to document in order to understand ways to modulate and increase 
SCFA production by enteric bacteria. This section discusses the metabolic pathways utilized in 
relation to the end-product produced- acetate, propionate, or butyrate. 
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Table 1: Properties of the Three Major SCFAs29,30 
 
 Acetate is the most abundantly produced SCFA and constitutes more than 50% of the 
SCFA composition in feces.30 Acetic acid’s structure is a carboxylic acid bonded to a single 
methyl group (Table 1) (Acetate: CH3 – COO-). Approximately one-third of acetate is produced 
by acetogenic bacteria.28 Acetogenic bacteria generate acetate from hydrogen and carbon dioxide 
or from formate via the Wood-Ljungdahl pathway.29 Through the Wood-Ljungdahl pathway, one 
molecule of glucose will produce 3 molecules of acetate.30 That being said, the majority of 
acetate is produced by colonic anaerobes through fermentation of carbohydrates from acetyl-
CoA.31 Anaerobes that produce acetate also utilize reducing equivalents to produce other 
products such as succinate, propionate, butyrate, formate, d-lactate, l-lactate, and ethanol.28  
Propionic acid’s structure is a carboxylic acid bonded to a methylene group bonded to a 
methyl group (Table 1) (Propionate: CH3 – CH2 – COO-). Colonic bacteria utilize three pathways 
to produce propionate: the succinate pathway, the acrylate pathway, and the propanediol pathway 
(Figure 2).28,31,32 The succinate pathway is the most widely utilized pathway by Firmicutes, 
Negativicutes and Bacteroidetes, to produce propionate.31 In this pathway, oxaloacetate from 
pyruvate goes through the TCA cycle to produce succinate as a substrate for the formation of 
propionate. The decarboxylation of methylmalonyl-CoA to form propionyl-CoA is specific to the 
succinate pathway.32 The second pathway used to produce propionate is the acrylate pathway. In 
Fatty Acid Structure 
Molecular 
Weight 
(g/mol) 
Boiling 
Point (C) 
Melting 
Point (C) 
Density 
Acetic Acid  CH3 – COOH 60.05 118 16.6 1.08 
Propionic Acid  CH3 – CH2 – COOH 74.1 141 -20.7 0.99 
Butyric Acid CH3 – (CH2)2 –COOH 88.1 163.5 -5.7 0.96 
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this pathway, lactoyl-CoA dehydratase and enzymatic reactions convert lactate to propionate.31 
This pathway is utilized by very few Firmicutes (Veillonellaceae and Lachnospiraceae  
families) and is not thought to produce a significant amount of propionate in the colon.31,32 
Distinct Firmicutes and Proteobacteria produce propionate via the propanediol pathway.28 The 
propanediol pathway is characterized by the conversion of deoxy-sugars (i.e. fucose and 
rhamnose) to propionate.28,31,32  Salonen et al conducted a study to evaluate the effects of dietary 
interventions on SCFA production and bacterial communities.33 The researchers saw that an 
increase in fecal Bacteroidetes concentration positively correlated to fecal propionate 
concentrations.33 This research suggests that Bacteroidetes (using the succinate pathway) are the 
primary producers of propionate in humans. 
Butyric acid’s structure is a carboxylic acid bonded to two methylene groups bonded to a 
methyl group (Figure 1) (Butyrate: CH3 – CH2 – CH2 – COO-). In the colon, butyrate is produced 
by gram-positive Firmicutes, most abundantly Eubacterium rectale/ Roseburia spp. and 
Faecalibacterium prausnitzii.34 The primary pathway in which enteric bacteria produce butyrate 
is the butyryl-CoA: acetate CoA-transferase pathway (see Figure 1).28, 31,34 In this pathway 
butyryl-CoA is produced form Acetyl-CoA. A single enzymatic reaction then converts butyryl-
CoA to butyrate.31 A less common pathway is the butyrate kinase pathway in which 
phosphotransbutyrylase and butyrate kinase enzymes convert butyryl-CoA into butyrate.28,31 
SCFA concentration in feces represents ~5% of the total concentration of SCFAs that are 
produced in the colon, while ~95% of the total SCFAs are rapidly absorbed and utilized by 
colonocytes or are put into systemic circulation. SCFAs are absorbed in the human colon and 
cecum at a comparable rate to that of the colonic and cecal mucosa of rats, with a higher rate of 
uptake seen in the distal colon compared to the proximal colon.35,36 Ruppin et al perfused the 
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colon of healthy individuals with an isotonic solution containing 0-90 mM of SCFAs and found 
that transport of SCFAs across colonocytes into circulation was primarily concentration 
dependent.37 The study identified two mechanisms of colonic SCFA absorption: simple diffusion 
of protonated SCFAs along with consumption of CO2 (~60% of SCFAs), and cellular uptake of 
ionized SCFAs along with ionic diffusion of sodium and potassium.35,37,38  
While the absorption of SCFAs is similar, the distribution and fate of SCFAs differ.28 
Oxidation of SCFAs, particularly butyrate, supplies 60-70% of the energy needs of colonocytes 
(even in the presence of glucose and glutamine which can also serve as substrates for 
colonocytes).35 Since butyrate is primarily utilized by epithelial cells, systemic circulation levels 
of butyrate are relatively low (1-3 mM).28,39 Propionate is primarily metabolized in the liver and 
peripheral blood concentrations of propionate are typically low (1-3mM).28,39 Acetate is the only 
SCFA to reach high concentrations in peripheral blood (100-150 mM). It is estimated that 
SCFAs constitute 5-10% of the average person’s total metabolizable energy per day.39 
Physiological Effects 
The role of the human microbiome in overall health is a major topic of current research; 
however, the mechanisms linking the microbiome to health status are largely unknown. Research 
suggests that a dysbiotic microbiome plays a causative role in several health conditions (e.g. 
metabolic disorders and inflammatory bowel disease).40,41 At the same time, a symbiotic 
microbiome is thought to protect against western diseases.40,41 It’s hypothesized that SCFAs may 
be the metabolic link between the human microbiome and health status.  
Both butyrate and propionate have been shown to inhibit histone deacetylases 
(HDACs).42 By inhibiting HDACs, butyrate is able to regulate gene expression and cellular 
differentiation. This suggests that butyrate may have an anti-carcinogenic effect in colonic 
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epithelial cells.28,41,42 Interestingly, butyrate has been shown to increase the proliferation of 
healthy colonocytes, thereby maintaining/ improving gut integrity; however, in the presence of 
transformed cells (cancerous colonocytes), butyrate induces terminal differentiation and 
apoptosis.43 This is because glucose is the primary fuel source for cancerous colonocytes (in 
normal colonocytes butyrate is the primary fuel source).43 As glucose is utilized by colonocytes, 
butyrate accumulates and functions as a HDAC inhibitor.43 
Acetate, propionate, and butyrate have also been shown to signal to free fatty acid 
receptors 2 and 3 (FFAR2, FFAR3), which are G-coupled protein receptors.39 Karaki et al 
demonstrated that FFAR2 is expressed in enteroendocrine cells in the ascending colon in 
humans.44 Further, activation of FFAR2 by SCFAs has been shown to facilitate/ modify peptide 
tyrosine tyrosine (PYY) secretion.39 PYY is a hormone that reduces appetite. Greenway et al. 
conducted a study to evaluate the effects of fermentable carbohydrates on PYY levels in healthy 
overweight and obese individuals.45 After 28 weeks, the researchers saw a significant increase in 
PYY and satiety 1-hr postprandial compared to baseline measurements (p<0.01).45 This research 
supports that SCFAs signal to FFAR2 and 3 receptors to increase secretion of PYY in the gut. As 
a result, increasing SCFA production may play a role in appetite regulation, which can be useful 
in the management of chronic diseases such as metabolic syndrome and overweight/obesity.  
SCFAs also act as mediators of intestinal and systemic immune function by inhibiting 
HDACs and by activating G-coupled protein receptors of leucocytes and endothelial cells.46 
SCFAs suppress lipopolysaccharide (LPS) and cytokine stimulated production of pro-
inflammatory markers (i.e. tumor necrosis factor- alpha, interleukin-6, and nitric oxide). 
Butyrate, in particular, been shown to enhance the release of interleukin-10, an anti-
inflammatory cytokine.46 Nastasi et al demonstrated that butyrate and propionate exert an 
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immunomodulatory effect by influencing gene expression in immature and mature human 
monocyte-derived dendritic cells.47 In the study, the researchers saw that propionate and butyrate 
inhibited the expression of LPS induced cytokines (IL-6 and IL-12).47 Further, the release of pro-
inflammatory chemokines (CCL3, CCL4, CCL5, CXCL9, CXCL10, and CXCL11) was 
significantly reduced following exposure.47 SCFAs also modify lymphocyte function by 
inhibiting T-cell proliferation, by reducing the production of pro-inflammatory cytokines, and by 
producing regulatory T-cells. SCFAs have been shown to improve inflammatory conditions such 
as inflammatory bowel disease, sepsis, and ischemia induced injury.45 
Probiotics 
Definition and Strains 
Probiotics, as defined by the world health organization, are live microorganisms that, 
when provided in adequate amounts, exert a beneficial effect to the host.48 Probiotics include 
several strains of Lactobacilli and Bifidobacteria as well as Escherichia coli strain Nissle 1917, 
Saccharomyces boulardii, and Streptococcus thermophilus.49 Probiotics are naturally found in 
yogurt, cheese, sauerkraut, kombucha, kefir, and kimchi. Animal and human studies show that 
probiotics can be supplemented to reduce diarrhea, prevent bacterial infections, manage 
gastrointestinal diseases, alleviate lactose intolerance and other allergies, and have anti-cancer 
effects; however, not all probiotic strains can be generalized to have these effects.50  
When considering the health benefits of probiotic supplements, several factors should be 
considered. For example, monostrain probiotics (single strain supplements) may have different 
effects compared to multistrain/multispecies supplements. Timmerman et al evaluated the 
survivability and activity of a multispecies culture collection containing five strains of 
Bifidobacterium (bifidum, breve, infantis, lactis, and longum), nine strains of Lactobaccillus 
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(acidophilus, brevis, bulgaricus, casei, helveticus, paracasei, plantarum, rhamnosus, and 
salivarius), as well as Enterococcus faecium, Lactococcus lactis, and Streptococcus 
thermophilus.51 Timmerman et al found that multispecies probiotics have increased functionality 
and efficacy in vivo compared to monostrain probiotic cultures.51 The researchers also found that 
different strains of probiotics exert different effects. Timmerman et al argue that B. bifidum, Lc. 
lactis, L. acidophilus and L. casei are potent immunomodulators while B. infantis, L. plantarum, 
L. rhamnosus and L. salivarius exhibit strong antimicrobial activity.51 That being said, there are 
currently no guidelines regarding the number of probiotic strains that are optimal for 
colonization and efficacy. Timmerman et al argues that certain strains, when encapsulated 
together, exert synergistic effects; however, certain strains, when incorporated into a multi-strain 
supplement, may inhibit the activity of other strains, thereby reducing the effectiveness of the 
multi-strain probiotic.51   
Probiotic strains used in supplements must be stable enough to withstand manufacturing, 
processing, storage, and transport. Additionally, the efficacy of a probiotic strain is dependent on 
its survivability in the presence of gastric juice in the stomach as well as enzymes and bile salts 
in the intestine.52 Time of probiotic exposure to these factors, degree of stomach acidity, and the 
concentration of bile salts will also affect viability of probiotics.52 Research suggests resistance 
to these factors is strain-dependent.52 For example, Madureira et al evaluated the survivability 
and stability of several strains of B. animalis, L. acidophilus, L. paracasei, and L. brevis when 
exposed to gastrointestinal conditions.53 Madureira et al found that all of the strains tested 
maintained their viability upon exposure to hydrochloric acid and pepsin (gastric juice); 
however, L. paracasei ssp. Paracasei LCS-1 and B. animalis BLC-1 experienced a severe 
decrease in viable cell numbers upon exposure to bile salts.52,53 
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Another significant factor affecting the efficacy of the probiotic supplement is the amount 
of colony forming units (CFUs) per capsule. The standard probiotic dose thought to be necessary 
to exert beneficial effects to the host ranges from 107 to 109 CFUs/mg/day.54 That being said, 
processing, storage, and gastrointestinal conditions will alter the CFUs of a given strain, 
affecting the strain’s survivability and overall effectiveness. Research suggests that >106 
CFUs/mL in the small intestine and >108 CFU/g in the colon is necessary to obtain clinically 
significant effects.54 The appropriate probiotic dosage will vary depending on the strain being 
supplemented, the frequency of supplementation, and the condition for which the probiotic is 
being supplemented. For example, in the management of acute infectious diarrhea, research 
suggests that a higher dosage is more effective than a lower dosage; however, higher dosages 
(>1010 CFUs/g) may not be necessary in the management of chronic conditions.54 Probiotic 
effects are likely dose-dependent and greater than 107 to 109 CFUs/mg/day is generally 
considered the effective dose in humans.54 
The physiological effects and overall efficacy of a probiotic supplement depends on each 
of these factors; however, the safety of the probiotic should also be considered. It is generally 
assumed that probiotics have an “acceptable known safety profile”; however, numerous genera, 
species, and strains are included under the umbrella term, probiotic, making it difficult to provide 
a safety assessment statement for all probiotics.55 Rather, probiotic safety should be determined 
on a strain-by-strain basis. Well-known and commonly used strains, such as Lactobaccillus, 
Bifidobacterium, and Saccharomyces have been determined to be safe for consumption for the 
general population; however, the manufacturing of the supplement can still impact the product’s 
overall safety.55 Low quality probiotic supplements should not be used in research and should 
not be recommended for consumption. Rather, only supplements that are made with Current 
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Good Manufacturing Practices (CGMP) and products that are Generally Recognized as Safe 
(GRAS), should be recommended and consumed.55 As a component of CGMP, probiotic 
supplements should also meet purity standards and should be manufactured under a quality 
management system.55 
Mechanism of Probiotic Action 
 Probiotics exert health benefits by influencing the composition and function of 
commensal microbiota, by altering host epithelial and the immune system, and by combating 
microbial and food toxins that adversely affect human health. That being said, the mechanism by 
which probiotics exert their ‘beneficial effect to the host’ is not well understood, this is most 
likely because probiotics do not have just one mechanism of targeted action. Mechanisms 
documented in literature include influence on gut barrier function, production of inhibitory 
substances, immune effects, blockage of adhesion sites, gut microbiota modulation, 
antiproliferative effects, competition for nutrients, and degradation of toxin receptors (Figure  
2).50  
 
Figure 1: Mechanism of Probiotic Action50 
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 One of the main effects of probiotics is colloquially referred to as “killing the bad 
bacteria.” While probiotics accomplish this through several mechanisms, one of the primary 
mechanisms is the production of antibacterial inhibitory substances, such as bacteriocins, organic 
acids, and hydrogen peroxide.50  Bacteriocins are peptides that are active against other bacteria 
most commonly by inhibiting cell wall synthesis and by destroying target cells by pore 
formation.50,56 Different strains of probiotics typically produce different bacteriocins. For 
example, Corr et al. found that Lactobacillus salivarius UCC118 produces bacteriocin Abp118.57 
Bacteriocin Abp118 has an antagonist effect against Listeria monocytogens and directly protects 
mice induced with Listeria monocytogens against infection.57 Bacteriocins produced by 
lactobacilli and Bifidobacteria have been shown to inhibit several pathogens, including E. coli, 
Heliobacter pylori, Listeria monocytogens, Rotavirus, and E. coli.50 Bacteriocins and organic 
acids such as lactic acid and SCFAs (byproducts of probiotics) also lower the pH within the GI 
tract. While lactic acid producing bacteria such as lactobacilli and Bifidobacteria can survive 
well in an acidic environment, many pathogenic bacteria cannot. 
 Another mechanism of probiotic efficacy is the ability to block adhesion sites for 
pathogen bacteria.50 Probiotic strains compete for adhesion sites along the epithelial surface of 
the gastrointestinal tract, inhibiting the colonization of pathogenic bacteria, causing pathogens to 
pass through the GI tract for excretion. Acid-resistant probiotics (i.e. Bifidobacterium longum 
and Bifidobacterium catenulatum) have demonstrated better adhesion to the epithelial surface 
compared to acid-sensitive strains. Additionally, multi-strain probiotics (i.e. VSL#3) can 
modulate gene expression and improve the adhesion of bacterial cells to the GI tract. 
Health promoting bacteria also compete more efficiently for nutrients, which prevents 
pathogen’s growth and proliferation. For example, while iron is an essential nutrient needed for 
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the survival of most bacteria, it is not needed for lactobacilli bacteria. Additionally, certain 
strains of Lactobacilli, such as L. acidophilus and L. delbrueckii, can bind ferric hydroxide at 
their cell surface, making iron less available for pathogens. This essentially creates an 
environment in which certain pathogens cannot survive.50 
Probiotics may also have anti-proliferative effects, as indicated in recent research. Certain 
probiotics are able to metabolically inactivate mutagenic substances, while others can bind 
heterocyclic aromatic amines and N-nitroso compounds to reduce DNA damage and levels of 
cancer-causing compounds.50 Additionally, probiotics influence on cytokine production and T-
cell function may promote anti-tumor activity by amplifying the immune response of tumor 
tissue.50 Research also shows that enhanced levels or lactobacilli and Bifidobacteria and lower 
amounts of Clostridium, coliforms, and Bacteroides are associated with reduced incidence of 
colorectal cancer.50 
Therapeutic Effects of Probiotics on GI Upset 
Probiotics likely have an indirect influence on SCFAs by enriching specific gut microbial 
populations that preferentially ferment carbohydrates.49 Meimandipour et al. found that 
supplementation of Lactobacillus agilis and Lactobacillus salivarius significantly increased 
production of lactate, propionate, and butyrate in vitro in cecal microflora of chickens.58 Another 
in vitro study conducted by Ogawa et al. showed that specific Lactobacillus species (L. casei and 
L. acidophilus) inhibited growth and activity of Shiga toxin-producing Escherichia coli 
O157:H7, a pathogenic bacterium.59 In vitro studies suggest that probiotics exert a positive effect 
on the microbiome by promoting the colonization of beneficial bacteria and by inhibiting the 
growth of opportunistic pathogens, both of which have an indirect effect on SCFA production. In 
vitro studies are beginning to be supported by human randomized controlled trials (RCT). In an 
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RCT conducted by Wang et al. the researchers supplemented 6.0 x 1010 CFUs/day of 
Lactobacillus plantarum to healthy individuals for four weeks.60 Fecal concentrations of 
Bifidobacterium significantly increased (p<0.05), concentrations of Desulfovibrio (an 
opportunistic pathogen) significantly decreased (p<0.05), and acetate and propionate 
concentrations significantly increased (p<0.05) after 4 weeks of supplementation.60 
Prebiotics 
Definition and Sources 
 A prebiotic is a food ingredient not digested in the upper GI tract that selectively 
stimulates the growth and/or activity of one or a limited number of bacteria in the colon.49 
Prebiotics also reduce non-beneficial (pathogenic) bacterial populations. Prebiotics include 
inulin, fructo-oligosaccharides, and resistant starch and are naturally found in foods such as 
beans, peas, oats, onions, garlic, tomatoes, and bananas. Fibers that act as prebiotics include 
cellulose, lignin, hemicellulose, pectins, and fructans (i.e. fructo-oligosaccharides and inulin). 
Therapeutic Effect of Prebiotics on GI Upset 
Numerous studies have documented the potential of prebiotics to increase SCFA 
production. Cardelle-Cobas et al demonstrated that galacto-oligosaccharides (GOS) stimulated 
Bifidobacteria growth and increased production of acetic acid in human fecal cultures (in 
vitro).61 In a similar study using fecal inocula incubation, Hernot et al found that short-chain 
oligosaccharides (e.g. NutraFlora, GTC Nutrition, Golden) were more rapidly fermented 
compared to long-chain oligosaccharides (e.g. inulin- Beneo ST and HP).62 In vitro, Lactobacilli 
concentrations increased similarly amongst short and long-chain oligosaccharides; however, 
Bifidobacteria concentrations significantly increased when short-chain oligosaccharides were 
fermented.62 The increase in Bifidobacteria was accompanied by an increase in gas, acetate and 
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propionate production in short-chain oligosaccharides.62 In a pilot human study conducted by 
Schwiertz et al, supplementing 15 grams of resistant starch per day for 28 days resulted in a 
significant increase fecal butyrate concentrations; however, total SCFA concentration remain 
unchanged.63 The research conducted by Cardelle-Cobas, Hernot, and Schwiertz suggest that 
prebiotics directly impact SCFA production.61,62,63 Further, prebiotic chain length influences 
fermentation rates, gas production, and microbial profiles.49 
Synbiotics 
Synbiotics are combination probiotic and prebiotic supplements. Many researchers 
hypothesize that synbiotics enhance colonic fermentation and promote gut symbiosis at a greater 
level than probiotics or prebiotic supplements that are administered alone.49,64 Grela et al 
conducted a study to evaluate the effects of multi-strain probiotics alone (Lactococcus lactis, 
Carnobacterium divergens, Lactobacillus casei, Lactobaccillus plantarum, and Saccharomyces 
cerevisiae), prebiotics alone (inulin), or both probiotics and prebiotics on select markers of the 
gastrointestinal system, including SCFA concentrations, in pigs.65 The concentration of 
propionic, butyric, and valeric acids increased significantly in the prebiotic group and in the 
prebiotic plus probiotic group when compared to a control group (p<0.05).65 A similar study was 
conducted in healthy individuals by Worthley et al (34). The researchers did not observe a 
significant change in SCFA concentrations in the probiotic group (Bifidobacterium lactis), the 
prebiotic group (high-amylose maize starch), or the synbiotic group (probiotic + prebiotic) after 
4 weeks.64 More research is needed to understand the effects of synbiotics on SCFA 
concentration in humans based on the above study and a general lack of available human 
research on synbiotics. That being said, results from studies on prebiotic and probiotic 
supplementation alone support the use of probiotics and prebiotics for the modulation of SCFAs. 
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Enzymes 
 Digestive enzymes include proteases, peptidases, lipases, amylases, nucleases, cellulases, 
and lactase. Digestive enzymes speed up and improve the breakdown of macromolecules (fats, 
carbohydrates, and proteins) into smaller molecules that are more easily absorbed.66 In addition 
to probiotics and prebiotics, digestive enzymes may improve gastrointestinal symptoms and may 
modulate the gut microbiome. Spagnuolo et al evaluated the effects of combination -glucan, 
inositol, and digestive enzyme supplementation on gastrointestinal symptoms of individuals with 
IBD and IBS.66 The researchers found a significant reduction in the intensity of abdominal pain 
(p<0.01), bloating (p<0.001), and flatulence (p<0.005) over 4 weeks; however the group did not 
experience any significant changes in inflammatory markers during the study.66 In another study 
conducted by Quinten et al, individuals with common gastrointestinal problems randomly 
received either domperidone (n=19) or Similase total (n=43).67 Similase total is an enzyme 
supplement that contains protease, cellulase, amylase, alpha galactosidase, maltase, lactase, 
lipase, invertase, and phytase, while domperidone (Motilium) is a common antiemetic and 
prokinetic medication for gastrointestinal disorders.68 Quinten et al found that participants 
receiving Similase total experienced a more significant reduction in abdominal pain compared to 
those receiving domperidone after 5 days of treatment (p=0.021).67 
In addition to improving gastrointestinal symptoms, digestive enzymes may influence the 
gut microbiome, however research is limited and nascent in this area. Nishiyama et al divided 
mice into two groups- the control, who received tap water, and the treatment group, who 
received lipase, amylase, and protease.69 The mice that received the enzyme treatment had a 
significantly different microbiota after 21 days.69 Specifically, treated mice had a higher 
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abundance of Akkermansia muciniphila and Lactobacillus reuteri, two beneficial commensal 
bacteria, in the cecum.69    
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CHAPTER 3 
MATERIALS AND METHODS 
Participant Selection 
Potential participants responded to a flyer advertised at East Tennessee State University 
sent through a mass email to students, faculty, and staff, or through advertisement at Johnson 
City health food stores, Johnson City community/ senior centers, and other retail establishments 
(See Appendix A). Potential participants were then screened for eligibility using a phone 
interview (See Appendix B). Participants met the following criteria of inclusion (1) self-reported 
presence of GI symptoms greater than 3 times per week (i.e. abdominal pain, heartburn, acid 
regurgitation, bloating, nausea and vomiting, abdominal distension, burping, increased gas, 
decreased passage of stools, increased passage of stools, loose stools, hard stools, urgent need for 
defecation, feeling of incomplete evacuation), (2) self-identified as healthy or having few health 
complications, and (3) over the age of 18 years old. Criteria of exclusion included (1) under the 
age of 18 years old, (2) diagnosis of Celiac disease, irritable bowel syndrome, inflammatory 
bowel disease (including Crohn’s disease and Ulcerative Colitis), (3) previous use/ consumption 
of GlutenShield, (4) current consumption of any prebiotics, probiotics, enzymes, non-steroidal 
anti-inflammatory drugs (NSAIDS), fish oil, and/or fiber supplements unless the participant was 
willing to halt use 2 weeks prior to beginning the study), (5) Recommendation/ prescription use 
of any NSAID, and (6) pregnancy or intention to become pregnant within 60 days. 
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Study Design 
The study was a split, 28-day randomized, partially blinded design. Eligible participants 
were administered an informed consent document by the principal investigator. After completing 
the informed consent, subjects were randomly assigned to one of two groups using a computer 
random number generator. Group A completed a 2-week washout of any probiotics, prebiotics, 
enzymes, NSAIDS, fish oil, and fiber supplements followed by a 28-day treatment period with 
GlutenShield taken 3x/day with meals. Group B completed the same 2-week washout followed 
by a 28-day placebo period with the placebo taken 3x/day with meals. Participants were blinded 
to which group/ treatment they were given. Subjects were provided a procedure form and 
materials to collect a stool sample at home when meeting to fill out the informed consent. 
On day zero of the active study, subjects arrived at Hutcheson Hall at ETSU and 
submitted a stool sample to the principal investigator. At this time, Dr. Kenneth Phillips 
collected two tubes of whole blood. Participants also completed a food frequency questionnaire, 
gastrointestinal symptoms questionnaire, and mood assessment on day zero. Participants were 
provided either a bottle of GlutenShield or a bottle of placebo pills. Participants were then 
instructed to take 3 pills per day with meals beginning on day 1 and lasting through day 28. On 
day 28, participants came back to Hutcheson Hall at ETSU and submitted a second stool sample 
to the principal investigator while Dr. Phillips again collected two tubes of whole blood. 
Participants also completed the gastrointestinal symptoms questionnaire and the mood 
assessment on day 28. Full review approval was obtained for this study by the ETSU 
Institutional Review Board (IRB) on December 5, 2017; study number 1117.22f. 
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Placebo and GlutenShield 
The placebo for the study was prepared by Dr. Charles Collins in the ETSU college of 
pharmacy. Each placebo capsule contained a 50/50 mixture of Avicel (cellulose) and of bentonite 
powder (to have a similar color as GlutenShield). The placebo was encapsulated in Vcaps 
Enteric and were made of cellulose. 
GlutenShield is a combination probiotic, prebiotic, and enzyme dietary supplement. 
Probiotics in GlutenShield include Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus 
rhamnosus, Bifidobacterium lactis, Lactobacillus plantarum, Lactobacillus brevis, Lactobacillus 
salivarius, Streptococcus thermophilus, Bifidobacterium bifidum, Lactobacillus coagulans, and 
Saccharomyces boulardii. Prebiotics in GlutenShield include Chitosan oligosaccharide, 
fructooligosaccharides, alfalfa, Emblica officinalis extract, papaya juice powder, fulvic acid, and 
ionic minerals. Enzymes in GlutenShield include dipeptyl peptidase IV (DPPV-IV), lactase, 
cellulase, hemicellulase, xylanase, phytase, serrapeptase, and plant-based digestive enzymes 
(lipase, protease, and amylase). 
Assessments 
Demographics and Food Frequency Questionnaire 
 On day 0 of the active trial, study participants completed NutritionQuest’s 2014 Block 
Food and Activity Questionnaire, a food frequency questionnaire (FFQ). The form measured 
usual dietary intake over the past month. Participants were instructed to report how often they 
consume a given food (i.e. cold cereal- once a month, 2-3 times per month, once per week, 2 
times per week, 3-4 times per week, 5-6 times per week, or every day), how much of the given 
food they consume in a given day (i.e. 1 glass of orange juice, 1 cup of cold cereal), and what 
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type of food they consume (i.e. low-fat, sugar-free). The questionnaire provided a detailed look 
at typical consumption of: 
• Eggs and dairy foods 
• Cereals, grains, and breads 
• Vegetables 
• Fruits 
• Beans, tofu, and meat substitutes 
• Soups, mixed dishes, and noodles 
• Meat and chicken 
• Fish and seafood 
• Nuts, seeds, and snacks 
• Sweets and desserts 
• Spreads, sauces, and other foods 
• Beverages 
From the self-reported intake, macronutrient and micronutrient intake was determined. In 
addition to reported typical food intake, respondents self-reported sex, age, weight, and height, 
from which body mass index (BMI) was calculated. Consumption of multiple and single 
vitamins and minerals as well as typical physical activity and ethnicity were also recorded.  
Gastrointestinal Symptoms Questionnaire  
 Participants completed the GI symptoms questionnaire on day 0, prior to the intervention, 
and on day 29, after the intervention. The questionnaire measured the severity of GI symptoms 
using a Likert numerical scale rating ranging from 1 (none) to 7 (always/severe) over the past 
week. GI symptoms measured included abdominal pain/ discomfort, heartburn, acid 
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regurgitation, bloating, nausea and vomiting, abdominal distension, eructation (burping), 
increased gas, decreased passage of stools, increased passage of stools (rapid transit), loose 
stools, hard stools, urgent need for defecation, and feeling of incomplete evacuation. The 
questionnaire was based off of Catassi et al’s Solerno experts diagnostic criteria.2 The 
questionnaire was administered in paper-and-pencil formation and took 3-5 minutes to complete.  
POMS Assessment 
 Participants completed MHS’s Profile of Mood States Second Edition adult short 
assessment (POMS 2-A-S) on day 0, prior to the intervention, and on day 29, after the 
intervention. The POMS short assessment was designed for adults ages 13 to 50+ and contained 
a subset of 35 items taken from the full-length assessment. The assessment provided a cursory 
evaluation of scaled scores for anger/ hostility, confusion/ bewilderment, depression/ dejection, 
fatigue/ inertia, tension/ anxiety, vigor/ activity, and friendliness. The assessment was used to 
evaluation changes in total mood disturbance at a given moment prior-to and following the 
intervention. The assessment was self-administered in paper-and-pencil format and took 3-5 
minutes to complete. Scores were measured using a t-score for each category that were 
automatically calculated by MHS Online Assessment Center. A t-score of >70 indicated a very 
elevated score, 60-69 indicated an elevated score, 40-59 indicated an average score, 30-39 
indicated a low score, and <30 indicated a very low score (see Table 2). 
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Table 2: POMS T-Score Classifications70 
T-Score Classification 
Negative Mood State Positive Mood State 
70+ Very Elevated Score (many 
more concerns than are 
typically reported) 
Very Elevated Score (Far 
fewer concerns than are 
typically reported) 
60-69 Elevated Score (more 
concerns that are typically 
reported) 
Elevated Score (Fewer 
concerns than are typically 
reported) 
40-59 Average Score (Typical 
levels of concern) 
Average Score (Typical 
levels of concern) 
30-39 Low Score (Fewer concerns 
than are typically reported) 
Low Score (More concerns 
than are typically reported) 
<30 Very Low Score (Far fewer 
concerns than are typically 
reported) 
 
Very Low Score (Many more 
concerns than are typically 
reported) 
 
Blood Collection and Analysis 
 Dr. Kenneth Phillips, associate dean of research for ETSU’s college of nursing collected 
10 mL of whole blood using a 23-gauge butterfly needle into two 8 ½ mL red-with-black top 
Becton Dickinson vacutainers per participant on day 0, prior to the intervention, and on day 29, 
post-intervention. The samples were put on ice and transported to ETSU’s health science 
laboratory were allowed to clot at room temperature for 30 minutes. The clot was removed by 
centrifuging the samples at 3000 x g for 10 minutes. One mL of the supernatant (serum) was 
transferred into a 1.5mL polypropylene Fisherbrand micro-centrifuge tube using am Eppendorf 
pipette. Two mL of serum was transferred to a 2.7 mL Fisher Scientific amber vial. The samples 
were stored at -80 Celsius for future analysis. ELISA analysis was performed using 
commercially available ELISA plates from Aviscera Bioscience. The remaining sample (2.7 mL) 
was banked for future analysis. 
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Fecal Collection 
 Following the informed consent meeting, participants were given a stool collection 
procedure form and were told how to collect a stool sample (See Appendix C). Participants were 
provided with saran (plastic) wrap, 4 self-sealing plastic bags, and 2 pairs of large nitrile gloves. 
Participants were instructed to collected 2 stool samples- one on day 0, prior to the intervention, 
and one on day 29, following the intervention. Participants collected the stool sample by lifting 
the toilet seat and placing a  layer of saran (plastic) wrap across the toilet, leaving a dip in the 
middle.  The bowel movement was then wrapped in the saran wrap, placed in a self-sealing 
plastic bag, and frozen in the freezer. Participants then transported the stool sample to Hutcheson 
Hall at ETSU on day 0 and day 29. Participants collected and froze the stool sample within 24-
hours of transporting the sample to ETSU. The stool samples were then stored on ice in a 
biohazard cooler and were transported to the Human Nutrition and Dietetics Research 
Laboratory on ETSU’s Valleybrook campus. At the laboratory, approximately 1 gram of fresh 
sample was separated and stored at -80 Celsius for future PCR microbiome analysis. The 
remaining sample was freeze-dried and used for nutrient analysis. 
Fecal Analysis 
Freeze Drying 
 The stool samples were freeze-dried using the FreeZone 2.5 Liter Freeze Dryer System. 
The instrument and refrigeration switch were turned on and allowed to reach -40 Celsius. Once 
-40C was reached, the vacuum was switched on and the instrument was ready for use. A 600 
mL LABCONCO freeze dry flask and lid was weighed and the tare weight was recorded. The 
pre-frozen stool sample was placed in the freeze-dry flask and the lid was sealed tightly. The 
flask, lid, and sample were weighed and the weight was recorded. The stool sample weight (wet 
 42 
weight) was then calculated and recorded. The sample was place on the freeze-dryer and was 
dried for ~48 hours at 0.077 mBar and -50 Celsius until all frost and cold spots were gone and 
the sample was thoroughly dry. The sample was removed from the freeze dryer and the flask, lid, 
and sample were weighed and the weight was recorded. The sample weight after freeze-drying 
(dry weight) and the percent dry weight were then calculated. Samples were then ground to a 
fine powder using an IKA M20 Universal Mill. 
Table 3: Freeze-Drying Calculations 
Freeze-Drying Calculations 
Wet Weight (flask + lid + sample before) – (flask + lid) 
Dry Weight (flask + lid + sample after) – (flask + lid) 
Percent Dry Matter Dry weight / Wet weight x 100 
 
Kjeldahl Digestion 
 Total nitrogen was determined for freeze-dried and ground samples using kjeldahl 
digestion. For the procedure, 100 mg of the sample was weighed (weight was recorded) into a 
100 mL kjeldahl flask along with 1.9 grams of potassium sulfate (K2SO4), 80 mg of mercuric 
oxide (HgO), 2 mL of concentrated (10N) sulfuric acid, and 2 porous boiling chips. The sample 
was placed on LABCONCO heat mantle. The air was turned on and the mantle was turned to 
heat setting 3. The sample refluxed for 8-12 hours, the heat mantle was then turned off, and the 
sample was cooled to room temperature. 15 mL of deionized distilled water (DDW) was added 
to the kjeldahl flask. The sample was brought to a boil and was filtered while hot into a 150 mL 
Erlenmeyer flask using P5 grade Fisher brand qualitative grade plain filter paper circles. 
Following digestion of the samples, distillation was performed to determine total nitrogen per 
sample. The LABCONCO rapid distillation unit was turned on, set to heat setting of 6-7, and 
was allowed to heat up. 5mL of 4% Boric acid and a few drops of kjeldahl indicator were added 
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to a new 150 mL Erlenmeyer flask. The flask was placed at the bottom of the distillation unit. 
The distillate (filtered sample) was added to the top of the unit and the Erlenmeyer flask was 
rinsed with DDW. The material was emptied into the reaction tube. 10 mL of sodium thiosulfate 
(NaOH/ Na2O3S2) was added to the top of the apparatus and was slowly emptied into the reaction 
tube. The sample was allowed to distill for 15-20 minutes until the total volume of the boric acid 
and ammonium solution reached 25-30 mL. During the distillation process, ammonium (NH4+) 
was converted to ammonia gas (NH3+). NH3+ condensed into the boric acid solution to form 
ammonium borate. The ammonium borate was then titrated with 0.1 N HCl until a color change 
was observed (blue→red; base→acid). The mL of HCl needed to titrate the solution back to an 
acid was recorded. Nitrogen per kilogram of sample and percent total protein were then 
calculated. Samples were run in duplicate.  
Table 4: Kjeldahl Calculations 
Kjeldahl Calculations 
Grams of Nitrogen per 
Kilogram of Sample 
(mL HCl titrated x 0.1N x 14.01) / weight of sample (grams) 
Percent Total Protein (g N per kg) x 6.25 / 1000g x 100 
 
Total, Soluble, and Insoluble Dietary Fiber Analysis 
 Total dietary fiber (TDF), soluble dietary fiber (SDF), and insoluble dietary fiber (IDF) 
was assessed on freeze-dried, ground stool samples using the automated ANKOM Dietary Fiber 
Analyzer method AOAC 991.43.72 Reagents were prepared as shown in Table 5. 
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Table 5: Fiber Reagent Methodology72 
Reagent Method 
78% ETOH Dilute 410.5 mL of 95% ETOH to 500 mL using DDW 
water in a 500 mL volumetric flask. 
Enzyme Solutions 
- -Amylase 
- Protease 
- Amyloglucosidase 
 
Dilute 5 mL of -Amylase to 25 mL using DDW 
Dilute 5 mL of Protease to 25 mL using DDW 
Dilute 5 mL of Amyloglucosidase to 25 mL using DDW 
MES-TRIS Buffer Dissolve 9.76 g of 2-(N-Morpholino)ethansulfonic acid 
(MES) and 6.1 g of Tris(hydroxymethyl)aminomethane 
(TRIS) in 850 mL of DDW. Adjust pH to 8.2 using 6N 
NaOH and dilute to 1 L with DDW 
Dilute HCl Solution (0.561N) Dilute 23.375 mL of 6N HCl  to 250mL in a volumetric flask 
using DDW. 
  
ANKOM IDF and SDF filter bags were labeled with a permanent marker. Each bag was weighed 
using the Bag Weigh Holder and an AL54 Mettler Toledo analytical balance. The tare bag 
weight was recorded onto a Dietary Fiber Data Spreadsheet (DFDS). One gram of Diatomaceous 
Earth was weighed into two separate dishes. The weight of each was recorded onto the DFDS. 
0.50.05 g of the freeze dried, ground stool sample was weighed in duplicate into two dishes. 
The weight of each was recorded onto the DFDS. All fluid levels were checked on the DF 
analyzer. The instrument and Nitrogen gas were turned on. SDF bags and Clamp Bar D were 
installed on the instrument. Clamp Bar D was closed and the pre-weighed DE was added to each 
SDF bag and was rinsed with 2-3mL of DI water. IDF bags and Clamp Bars B and C were 
installed onto the instrument. Clamp Bar B was closed, pinching off the bags, and the pre-
weighed samples were transferred to the IDF bags. SDF bags were hooked to Clamp Bar C. 
Clamp Bar A was installed. The instrument was started, beginning the automated process of 
digesting the sample. After the amylase and protease phases, the pH of the samples was checked 
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and adjusted to 4.0-4.7 as needed with 0.561N HCl. After the automated process was complete, 
IDF and SDF bags were rinsed with Acetone using the ANKOM Acetone Rinse Stand. After 
drying, the bags were sealed at a heat setting of 3 using the ANKOM Heat Sealer. Samples were 
placed on a drying rack and were placed in a Fisher Scientific Isotemp oven at 100 Celsius for 
90 minutes. Samples were removed from the oven and immediately placed in an ANKOM 
MoistureStop weigh pouch (desiccant pouch) to cool. Bags were removed one at a time from the 
desiccant pouch and were weighed on an analytical scale using the Bag Weigh Holder. Bag 
weights were recorded on the DFDS. A protein correction was performed using kjeldahl 
digestion and distillation, as described above. An ash correction was also performed by burning 
the samples as 700 Celsius for 5 hours and recording the weight after ashing. All ashing and 
protein values were recorded on the DFDS. Percent IDF, SDF and TDF were then calculated 
using the following equations: 
• %IDF or %SDF = (Residue (grams) – protein residue and bag – ash residue and bag – 
blank) / original weight of sample x 100% 
• TDF = %IDF + %SDF 
SCFA Extraction and Determination 
 SCFA extractions were performed using a procedure developed by Schwiertz et al. that 
was modified.73 One mL of the SCFA extraction solution, containing Oxalic acid (0.1 mol/L), 
Sodium Azide (40 mmol/L), and Caproic acid (0.1 mmol/L )(internal standard) was added to 80 
mg of a freeze-dried stool sample in a 16 x 100 mm disposable culture tube. The tube was 
capped and vortexed for 30 seconds. The tube was placed on a horizontal shaker for 1 hour. The 
tube was centrifuged at 4000 rpm for 20 minutes. After centrifuging, the supernatant  was 
removed and placed in a 1.5mL polypropylene Fisherbrand micro-centrifuge tube. The solution 
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was re-centrifuged at 12,000 rpm for 15 minutes. Again, the supernatant was removed and 
placed in a new 1.5 mL micro-centrifuge tube. The solution was re-centrifuged at 12,000 rpm for 
15 minutes. Finally, the supernatant was removed, placed in a 2 mL amber vial, and was stored 
at -80 Celsius until being analyzed using a Shimadzu GC2010 gas chromatograph with Sigma-
Aldrich ZB-Wax Plus capillary column. Samples were run using the SCFA.standard.run.gcm 
method adapted from Schaefer et al. shown in Table 6.74 
Table 6: SCFA Gas Chromatography Methodology74 
SCFA.standard.run.gcm Method 
Injection Volume 1 L 
SPL1 Temperature 750 Celsius 
Column Parameters: Initial temperature: 50 Celsius 
Rate 
Temperature 
( C) 
Hold 
(minutes) 
- 50 2 
15 140 5 
10 160 3 
10 175 3 
 
FID1 Temperature 180 Celsius 
End Time 24 minutes 
 
Statistical Analysis 
 Descriptive statistics and subsequent analyses were performed using GraphPad Prism. 
General linear models were used for all statistical analysis to determine change over time within 
the treatment and placebo groups and to determine differences between treatment and placebo 
participants. Change over time within a group and differences between groups were considered 
significantly significant if a p-value of less than 0.05 was achieved. Standard deviations were 
also determined for all dependent variables. 
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CHAPTER 4 
RESULTS 
Participants 
 Twenty-two participants were enrolled in the study per eligibility criteria. Two 
participants were removed from the study, and 20 participants completed the study. One 
participant was removed for an injury unrelated to the study that prevented further continuation. 
The other was removed for experiencing increased gastrointestinal symptoms while taking the 
placebo. Of the 20 that completed the study, group one included 10 participants that took the 
treatment (GlutenShield) three times a day for 28 days and group two included 10 participants 
that took the placebo three times a day for 28 days. 
Demographics 
 The overall cohort (n=20) had a mean age of 42  17.11, with a mean age of 46.80  
17.25 for the treatment group and a mean age of 37.2  16.42 for the placebo group. The total 
cohort was comprised on 30% males (n=6) and 70% females (n=14) with 3 males and 7 females 
in both the treatment and placebo groups. The mean BMI for the overall cohort was 28.61  
7.26, with a mean BMI of 24.79  6.42 for the treatment group and a mean BMI of 31.49  7.21 
for the placebo group. The treatment group was comprised of 60% normal weight (NW) adults 
(n=6), 30% overweight (OW) adults (n=3), and 10% obese (OB) adults (n=1) using BMI 
classification. The placebo group was comprised on 20% NW adults (n=2),  30% OW adults 
(n=3), and 50% OB adults (n=5). In the overall cohort, 90% (n=18) identified as Caucasian, 
while 10% (n=2) identified as other. Demographic results are shown in Table 7. 
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Table 7: Demographics 
 
Overall Cohort Treatment 
Group 
Placebo 
Group 
p* 
N 20 10 10 
 
Gender 
    
Male gender n (%) 6 (30%) 3 (30%) 3 (30%) 1.000 
Female gender n (%) 14 (70%) 7 (70%) 7 (70%) 1.000 
BMI 
    
BMI (kg/m2)  28.61 ± 7.26 24.79 ± 6.42 31.49 ± 7.21 0.078 
-Normal Classification (%) 8 (40%) 6 (60%) 2 (20%) 0.074 
-Overweight Classification (%) 6 (30%) 3 (30%) 3 (30%) 1.000 
-Obese Classification (%) 6 (30%) 1 (10%) 5 (50%) 0.054 
Ethnicity 
    
Caucasian 18 (90%) 9 (90%) 9 (90%) 1.000 
Other 2 (10%) 1 (10%) 1 (10%) 1.000 
Age (years) 42.0 ± 17.11 46.80 ± 17.25 37.2 ± 16.42 0.219 
 
 
Assessments 
Food Frequency Questionnaire and Physical Activity 
 Results from NutritionQuest’s 2014 Block Food and activity questionnaire are shown in 
Tables 8 through 12. Meal frequency for the cohort (n=20) averaged 2.63  0.60 and snack 
frequency averaged 1.89  0.90 (see Table 8). There were no significant differences in 
macronutrient distribution between groups (p>0.05). For the total cohort, daily energy intake 
averaged 1543.41  517.95 calories, protein intake averaged 60.26  23.83 grams (15.62% of 
total caloric intake), carbohydrate intake averaged 171.72  62.29 grams (44.50% of total caloric 
intake), total fat intake averaged 67.65  27.92 grams (39.46% of total caloric intake), fiber 
intake averaged 15.22  7.45 grams, insoluble fiber intake averaged 10.86  6.17 grams, and 
soluble fiber intake averaged 4.02  1.73 grams. A more detailed breakdown of macronutrient 
intakes in shown in Table 9.  
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Table 8: FFQ: Meal/Snack Frequency 
 
Meal/Snack Frequency 
Item (per day) Treatment Group 
(mean  std.) 
Placebo group 
(mean  std.) 
Total Cohort 
(mean  std.) 
p* 
Meal frequency  
 
2.6  0.52 2.67  0.71 2.63  0.60 0.816 
Snack frequency  
 
1.8  0.79 2.00  1.07 1.89  0.90 0.654 
 
Table 9: FFQ: Macronutrient/ Other Intake 
 
 
Macronutrient/ Other 
Item (per day) Treatment Group 
(mean  std.) 
Placebo group 
(mean  std.) 
Total Cohort 
(mean  std.) 
p* 
Energy, total (kcals) 
 
1609.40  463.41 1447.41  584.75 1543.41  517.95 0.583 
Protein (g) 
 
64.32  21.67 56.20  26.31 60.26  23.83 0.461 
Carbohydrates (g) 
 
178.98 50.44 164.45  74.36 171.72  62.29 0.615 
Total fat  (g) 
 
69.32  29.97 65.99  27.23 67.65  27.92 0.797 
Saturated fat (g) 
 
21.02  8.49 22.08  9.78 21.54  8.93 0.799 
Monounsaturated fat 
(g) 
26.07  11.20 24.97  10.22 25.52  10.45 0.822 
Polyunsaturated fat 
(g) 
16.45  9.09 13.34  5.48 14.92  7.48 0.358 
Cholesterol (mg) 
 
211.86  93.93 218.23  101.85 215.08  95.41 0.885 
Alcohol (g) 
 
5.73  6.31 4.47  5.06 5.10  5.60 0.630 
Total sugar (g) 
 
72.59  35.47 75.93  43.82 74.26  38.84 0.853 
Total fiber (g) 
 
16.69  6.97 13.75  7.99 15.22  7.45 0.392 
Insoluble fiber (g) 
 
12.04  5.92 9.67  6.49 10.86  6.17 0.403 
Soluble fiber (g) 
 
4.55  1.91 3.48  1.43 4.02  1.73 0.175 
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Intake of grains, whole grains, vegetables, fruit, dairy, protein, and beneficial oil intake is 
also shown in Table 10. Results are reported in equivalents shown in relation to the United States 
Department of Agriculture’s Dietary Guidelines for Americans/ MyPlate recommendations. 
Grain intake averaged 4.04  2.34 oz per day, whole grain intake averaged 0.92  0.58 oz per 
day, vegetable intake averaged 1.06  0.63 cups per day, fruit intake averaged 0.73  0.75 cups 
per day, dairy intake averaged 1.26  0.65 cups per day, protein intake averaged 5.2  3.88 oz 
per day, and beneficial oil intake averaged 5.11  2.67 teaspoons per day. All p-values for 
measurement between groups for MyPlate equivalents were greater than 0.05. When comparing 
intakes of food groups to the MyPlate recommendations, the total cohort averaged a lower intake 
of grains (average intake (AI) : 4.04  2.34, recommended intake (RI): 5 oz equivalent), whole 
grains (AI: 0.92  0.58, RI: 3 oz-equivalent),  fruit (AI: 0.73  0.75, RI: 1.5 cup equivalent), 
dairy (AI: 1.26  0.65, RI: 2.5 cup equivalent), and beneficial oils (AI: 5.11  2.67, RI: 17 
grams) based on a 1,400 calorie meal pattern.75 
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Table 10: FFQ: MyPlate Equivalents 
 
 Micronutrient distribution of daily vitamin and mineral intake is shown in Table 11. No 
significant differences were indicated between groups for micronutrient intake (p>0.05). Physical 
activity results are shown in Table 12. Overall daily estimated energy expenditure for all 
activities averaged 730.09  565.16 calories and estimated activity expenditure excluding work 
and chores averaged 206.65  245.84 calories per day. Minutes spent performing activities per 
day averaged 89.79  66.42 for light activity, 46.51  67.86 for moderate activity, and 18.44  
23.59 for vigorous activity. 
  
MyPlate Equivalents 
Item (per day) Treatment 
Group (mean  
std.) 
Placebo group 
(mean  std.) 
Total Cohort 
(mean  std.) 
P* 
Grain (oz) 
 
4.34  1.63 3.74  3.0 4.04  2.34 0.512 
Whole grain (oz) 
 
1.16  0.65 0.67  0.40 0.92  0.58 0.060* 
Vegetable, total (no 
legume or potato) (cup) 
1.30  0.71 0.83  0.47 1.06  0.63 0.100 
Vegetable, potato and 
legume (cup) 
0.29  0.22 0.20  0.12 0.25  0.18 0.265 
Fruit, total (including 
juice) (cup) 
0.53  0.38 0.93  0.98 0.73  0.75 0.247 
Dairy, total (cup) 
 
1.23  0.60 1.29  0.73 1.26  0.65 0.847 
Protein foods: meat, 
poultry, seafood (oz) 
3.23  1.68 3.12  1.89 3.17  1.74 0.894 
Protein foods: nuts and 
seeds (oz) 
1.34  1.60 0.66  0.52 1.00  1.21 0.217 
Protein foods: eggs (oz) 
 
0.40  0.23 0.42  0.32 0.41  0.27 0.875 
Protein foods: legumes and 
soy (oz) 
0.92  0.85 0.33  0.12 0.62  0.66 0.042* 
Beneficial oils (tsp) 
 
5.63  3.27 4.59  1.94 5.11  2.67 0.398 
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Table 11: FFQ: Micronutrient Intake 
Micronutrient Intake 
Item (per day) Treatment Group 
(mean  std.) 
Placebo group 
(mean  std.) 
Total Cohort 
(mean  std.) 
P* 
Vitamin A (mg) 
 
631.70  251.54 494.81  158.12 563.25  216.20 0.162 
Vitamin E (mg) 
 
8.25  3.53 6.19  1.82 7.22  2.93 0.118 
Vitamin E, added 
(mg) 
0.56  0.90 0.26  0.20 0.41  0.65 0.311 
Vitamin D (mcg) 
 
4.06  1.97 2.93  1.22 3.49  1.70 0.141 
Vitamin K (mcg) 
 
128.82  75.79 82.30  36.54 105.56  62.63 0.097 
Vitamin C (mg) 
 
53.12  25.33 56.22  30.04 54.67  27.09 0.806 
Thiamin (mg) 
 
1.90  1.07 1.58  0.76 1.74  0.92 0.451 
Riboflavin (mg) 
 
1.27  0.39 1.04  0.50 1.15  0.45 0.265 
Niacin (mg) 
 
21.41  9.22 19.01  9.43 20.21  9.16 0.573 
Vitamin B6 (mg) 
 
1.93  1.34 1.74  0.81 1.84  1.08 0.713 
Folate (mcg) 
 
340.02  103.41 250.52  95.79 295.27  107.33 0.060* 
B12 (mcg) 
 
4.61  2.83 4.05  2.41 4.33  2.58 0.642 
B12, added (mcg) 
 
1.25  2.43 1.03  2.41 1.14  2.58 0.790 
Choline (mg) 
 
261.62  89.50 220.77  80.70 241.19  85.55 0.298 
Calcium (mg) 
 
734.12  212.29 717.08  319.12 725.60  263.94 0.890 
Iron (mg) 
 
12.014  4.18 9.19  3.58 10.60  4.05 0.122 
Magnesium (mg) 
 
277.62  107.21 208.27  66.95 242.94  93.99 0.100 
Phosphorus (mg) 
 
1102.78  335.95 984.69  421.37 1043.73  375.81 0.497 
Potassium (mg) 
 
 2323.44  758.70 1814.77  703.89 2069  758.58 0.536 
Sodium (mg) 
 
2830.11  871.24 2529.48  1228.33 2679.80  1047.87 0.536 
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Zinc (mg) 
 
9.92  3.13 8.13  3.68 9.02  3.45 0.257 
Copper (mg) 
 
1.25  0.55 0.95  0.27 1.10  0.45 0.141 
Selenium (mg) 
 
85.19  27.66 73.08  36.40 79.14  32.07 0.413 
Caffeine (mg) 
 
189.19  111.93 120.59  109.75 155.16  113.57 0.180 
 
 
 
Table 12: FFQ: Physical Activity 
Physical Activity 
Category (per day) Treatment 
Group (mean  
std.) 
Placebo group 
(mean  std.) 
Total Cohort 
(mean  std.) 
P* 
Estimated energy 
expenditure, all activities 
(kcals) 
497.85  331.73 939.10  662.21 730.09  565.16 0.089 
Estimated energy 
expenditure, excluding 
work and chores (kcals) 
153.62  155.49 254.38  306.67 206.65  245.84 0.388 
Estimated light activity 
(minutes) 
78.36  60.50 101.23  73.23 89.79  66.42 0.456 
Estimated moderate 
activity (minutes) 
36.09  31.62 56.93  92.08 46.51  67.86 0.507 
Estimated vigorous activity 
(minutes) 
11.29  15.25 25.60  28.79 18.44  23.59 0.182 
Estimated recreation 
(minutes) 
23.17  19.51 24.61  29.01 23.89  24.07 0.898 
 
 
Gastrointestinal Symptoms 
 
 Participants completed a gastrointestinal symptoms (GIS) questionnaire using a 7-point 
Likert scale. Symptoms measured included heartburn, acid regurgitation, bloating, nausea, 
abdominal distension, eructation, increased gas, decreased passage of stools, increased passage 
of stools, loose stools, hard stools, urgent need for defecation, and feeling of incomplete 
evacuation. Out of a possible 91 points, the participants averaged a GIS score of 28.9  9.65. The 
treatment group had a pre mean GIS score of 29.4  9.18 and a post mean GIS score of 22.9  
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6.42 (p=0.083091). The placebo group had a pre mean GIS score of 28.4  10.57 and a mean 
post GIS score of 21.2  6.29 (p=0.080676). A mean reduction of 6.5 points was observed in the 
treatment group, while a mean reduction of 7.2 points was observed in the placebo group. A 
significant reduction in bloating (3.6  1.65 vs. 2.3  0.82, p=0.038475) was observed in the 
treatment group. An approaching significant reduction was observed for loose stools in the 
treatment group (2.5  1.18 vs. 1.6  0.84, p=0.065169). An approaching significant reduction 
was also observed in the placebo group for bloating (3.1  1.66 vs. 1.9  0.99, p=0.065897) and 
increased gas (2.1  1.45 vs. 1.8  1.30, p=0.066324). Starting values from both groups were 
compared and no significant differences were observed for heartburn (p=0.47), acid regurgitation 
(p=0.18), bloating (p=0.51), nausea (p=0.38), abdominal distension (p=0.62), eructation 
(p=0.31), increased gas (p=0.89), decreased passage of stools (p=0.89), increased passage of 
stools (p=0.52), loose stools (p=0.60), hard stools (p=0.70), urgent need for defecation (p=0.79), 
feeling of incomplete evacuation (p=0.64), or total GIS (p=0.82). Change from pre to post and 
significance for the treatment and placebo groups are shown in Table 13. 
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Table 13: Gastrointestinal Symptoms  
Gastrointestinal Symptoms 
 
Symptom Treatment 
Pre  
(mean  
stdev.) 
Treatment 
Post 
(mean  
stdev.) 
Treat-
ment p* 
 
Placebo 
Pre 
(mean  
stdev.) 
Placebo 
Post 
(mean  
stdev.) 
Placebo 
p* 
Delta  
between 
groups 
p* 
Heartburn 
 
1.6  0.97 1.1  0.32 0.137 2.0  1.41 1.8  0.79 0.701 0.569 
Acid 
Regurgitation 
1.1  0.32 1.2  0.63 0.660 1.5  0.85 1.6  1.07 0.820 1.000 
Bloating 
 
3.6  1.65 2.3  0.82 0.038* 3.1  1.66 1.9  0.99 0.066* 0.894 
Nausea 
 
1.4  0.96 1.2  0.42 0.556 1.8  1.03 1.1  0.32 0.055* 0.216 
Abdominal 
Distension 
2.9  1.45 1.9  1.29 0.120 2.5  2.01 1.4  0.52 0.112 0.889 
Eructation 
 
2.9  1.91 2.0  1.33 0.238 2.1  1.45 1.8  1.03 0.600 0.472 
Increased Gas 
 
3.0  1.76 2.2  1.03 0.232 2.9  1.29 1.8  1.30 0.066* 0.675 
Decreased 
Passage of 
Stools 
2.0  1.15 1.9  1.85 0.886 1.9  2.02 1.9  1.60 1.000 0.911 
Increased 
Passage of 
Stools 
1.9  1.10 2.1  1.45 0.732 1.5  1.58 1.5  0.85 1.00 0.812 
Loose Stools 
 
2.5  1.18 1.6  0.84 0.065* 2.9  2.02 1.8  1.32 0.167 0.748 
Hard Stools 
 
2.0  1.25 1.8  1.23 0.722 1.8  1.03 1.6  0.70 0.618 1.000 
Urgent Need 
for Defecation 
2.1  1.60 1.5  0.53 0.274 2.3  1.64 2.1  1.45 0.343 1.000 
Feeling of 
Incomplete 
Evacuation 
2.4  1.35 2.1  1.52 0.647 1.7  1.06 1.3  0.48 0.115 0.247 
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*Each color in the graph represents an individual participant in the study 
Figure 2: Change in Mean GI Symptoms in Treatment and Placebo Groups 
 The change in treatment group compared to the change in placebo group was 
insignificant for heartburn (p=0.569275418), acid regurgitation (p=1.00), bloating 
(p=0.894446423), nausea and vomiting (p= 0.216268549), abdominal distension 
(p=0.888985282), eructation (0.426753529), increased gas (p=0.674699956), decreased gas 
(p=0.911541284), increased passage of stools (p=0.811708962), loose stools (p=0.747918259), 
hard stools (p=1.00), urgent need for defecation (p=1.00), feeling of incomplete evacuation 
(p=0.246784597), and total GI symptoms (p0.836516559).  
POMS Assessment 
The Profile of Mood States self-assessment measured initial and change in mood states 
for anger/ hostility, confusion/ bewilderment, depression/ dejection, fatigue/ intertia, tension/ 
anxiety, vigor/ activity, and friendliness. Measurements are reported as a t-score calculated by 
MHS Assessments. The starting mean t-score for both the treatment and placebo groups within 
each category fell within the typical score range (t-score of 40-59). Additionally, there was no 
significant change over time in either group, nor was there a significant difference between 
groups. Change from pre to post and significance for the treatment and placebo groups are shown 
in Table 14. 
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Table 14: POMS T-Scores 
 
POMS (T-Score) 
 Treatment 
Pre 
(mean  
stdev.) 
Treatment 
Post 
(mean  
stdev.) 
Treat-
ment p* 
Placebo 
Pre 
(mean  
stdev.) 
Placebo 
Post 
(mean  
stdev.) 
Placebo 
p* 
Delta  
between 
groups 
p* 
Total Mood 
Disturbance 
44.5  5.44 45.3  9.87 0.825 44.1  
4.23 
42.2  
5.51 
0.399 0.373 
Anger-
Hostility 
40.3  2.63 42.5  7.17 0.374 42.1  
5.55 
40.0  
1.76 
0.269 0.165 
Confusion-
Bewilderment 
43.2  3.77 43.4  6.15 0.931 42.0  
3.94 
41.5  
3.81 
0.776 0.765 
Depression-
Dejection 
43.0  2.0 44.8  7.89 0.493 43.8  
3.05 
44.0  
2.0 
0.864 0.508 
Fatigue-
Inertia 
44.4  9.23 44.8 10.25 0.928 38.8  
5.14 
38.3  
5.29 
0.833 0.712 
Tension-
Anxiety 
41.5  5.40 42.0  7.20 0.862 41.9  
4.82 
41.9  
4.53 
1.000 0.864 
Vigor-Activity 47.0  7.63 48.8 10.80 0.664 44.2  
8.35 
49.4  
8.67 
0.189 0.283 
Friendliness 53.1  3.48 54.7  9.24 0.614 48.0  
8.06 
47.6  
10.95 
0.927 0.549 
 
Blood Analysis 
Immunoglobins 
 The concentration of immunoglobins (ug/mL) IgG1, IgG2, IgG3, IgG4, IgA, and IgM 
was measured via ELISA analysis of the pre and post blood samples of each participant in 
duplicate. An approaching significant reduction was observed for IgG1 in the treatment group 
(7344.04  2381.53 vs. 5094.64 vs  2729.10, p=0.0651850) with no significant change from pre 
to post measured in the placebo group (8986.89  2753.77 vs. 7901.47  2919.83, p=0.429088). 
A significant reduction was observed in the treatment group for IgG2 from pre to post (7110.44 
 2437.07 vs. 4185.56  1901.13, p=0.007813) with no significant change observed in the 
placebo group from pre to post (7748.76  3024.44 vs. 5710  1975.02, p=0.109788). No 
changes were seen from pre to post in either the treatment or placebo groups for IgG3, IgG4, 
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IgA, or IgM. No significant changes were observed when comparing the change in the treatment 
group to the change in the placebo group for all immunoglobins (p>0.05). Change from pre to 
post and significance for the treatment and placebo groups are shown in Table 15. 
Table 15: Immunoglobins 
Immunoglobins (ug/mL) 
 Treatment 
Pre 
(mean  
stdev.) 
Treatment 
Post 
(mean  
stdev.) 
Treat-
ment p* 
Placebo 
Pre 
(mean  
stdev.) 
Placebo 
Post 
(mean  
stdev.) 
Placebo 
p* 
Delta  
between 
groups 
p* 
IgG1 7344.04  
2381.53 
5094.64  
2729.10 
0.065* 8986.89  
2753.77 
7901.47  
2919.83 
0.429 0.304 
IgG2 7110.44  
2437.07 
4185.56  
1901.13 
0.008* 7748.76  
3024.44 
5710  
1975.02 
0.110 0.462 
IgG3 693.4  
518.92 
505.76  
451.30 
0.400 664.4  
362.62 
589.29  
336.46 
0.655 0.443 
IgG4 342.4  
271.51 
257.6  
241.49 
0.470 585.38  
532.20 
564.89  
533.61 
0.936 0.276 
IgA 2046.24  
711.41 
1662.92  
835.30 
0.284 2316.09  
1058.41 
2197.42  
987.08 
0.809 0.301 
IgM 2247.4  
1458.65 
1683.84  
1614.82 
0.424 2136.4  
1373.22 
1855.02  
976.04 
0.623 0.523 
 
Cytokines 
The concentration of cytokines (pg/mL) IL-2, IL-6, IL-8, and TNF-a was measured via 
ELISA analysis of the pre and post blood samples of each participant in duplicate. No significant 
changes were seen from pre to post in the treatment group for all measures. A significant 
decrease was measured from pre to post in the placebo group for TNF-a (35.30  8.32 vs. 26.01 
 7.70, p=0.018498). No significant differences were observed when comparing the change in 
the treatment group to the change in the placebo group (p>0.05). Change from pre to post and 
significance for the treatment and placebo groups are shown in Table 16. 
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Table 16: Cytokines 
Cytokines (pg/mL) 
 Treatment 
Pre 
(mean  
stdev.) 
Treatment 
Post 
(mean  
stdev.) 
Treat-
ment p* 
Placebo 
Pre 
(mean  
stdev.) 
Placebo 
Post 
(mean  
stdev.) 
Placebo 
p* 
Delta  
between 
groups 
p* 
IL-2 3.07  1.43 2.36  0.64 0.172 2.32  0.82 2.46  0.67 0.663 0.144 
IL-6 2.23  0.30 2.21  0.40 0.921 2.21  0.29 2.14  0.37 0.659 0.768 
IL-8 10.32  2.78 9.27  2.03 0.344 9.35  1.79 9.35  1.10 0.998 0.288 
TNF-a 49.8  39.77 31.7013.72 0.190 35.30 8.32 26.017.70 0.018* 0.397 
 
Fecal Analysis 
Freeze Drying 
 No significant change was observed in the dry weight (grams) of the stool sample from 
pre to post in the treatment (13.19  10.37 vs. 11.45  9.81, p=0.704937) or placebo groups 
(21.12  15.57 vs. 20.98  15.06, p=0.563617). The treatment group began with a mean percent 
dry weight of 25.94  5.52 and ended with a mean percent dry weight of 26.87  5.64 
(p=0.713393). The placebo group began with a mean percent dry weight of 27.75  5.80 and 
ended with a mean percent  dry weight of 26.04  7.16 (p=0.563617). The delta (change in) dry 
weight mass was not significant between groups (p=0.756729), nor was the delta % dry weight 
(p=0.385334). Change from pre to post and significance for the treatment and placebo groups are 
shown in Table 17. 
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Table 17: Freeze-Drying Dry Weights 
Dry Weight 
 Treatment 
Pre 
(mean  
stdev.) 
Treatment 
Post 
(mean  
stdev.) 
Treat-
ment p* 
Placebo 
Pre 
(mean  
stdev.) 
Placebo 
Post 
(mean  
stdev.) 
Placebo 
p* 
Delta  
between 
groups 
p* 
Dry 
Weight 
(g) 
13.1910.37 11.45  9.81 0.705 21.12  
15.57 
20.9815.06 0.984 0.757 
Dry 
Weight 
(%) 
25.94  5.52 
 
26.87  5.64 0.713 27.75  
5.80 
26.04  7.16 0.564 0.385 
 
Protein 
 No significant change was observed in the total percentage of protein of the stool sample 
from pre to post in the treatment (28.32  6.73 vs. 33.39  10.10, p=0.236885) or placebo groups 
(30.45  5.49 vs. 30.14  8.02, p=0.925755). The change in protein percentage in the treatment 
group compared to the change in the protein percentage in the placebo group was also non-
significant (p=0.28021). Change from pre to post and significance for the treatment and placebo 
groups are shown in Table 18. 
Table 18: Percent Protein 
 
Protein (%) 
Treatment 
Pre 
(mean  
stdev.) 
Treatment 
Post 
(mean  
stdev.) 
Treat-
ment p* 
Placebo Pre 
(mean  
stdev.) 
Placebo Post 
(mean  
stdev.) 
Placebo 
p* 
Delta  
between 
groups p* 
28.32  6.73 33.39  10.10 0.237 30.45  5.49 30.14  8.02 0.926 0.280 
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Fiber 
 Percentage of insoluble, soluble, and total dietary fiber was measured from freeze-dried 
stool samples using an ANKOM Dietary Fiber Analyzer in duplicate. In the treatment group, no 
significant change was measured for percentage of insoluble dietary fiber (41.54  10.72 vs 
39.92  7.12, p=0.686656), soluble dietary fiber (10.33  4.86 vs. 12.24  6.59, p=0.50162), or 
total dietary fiber (51.88  10.39 vs. 53.04  7.79, p=0.779015). In the placebo group, there was 
no significant change in the percentage of soluble dietary fiber (15.49  16.46 vs. 10.51  3.81, 
p=0.389839) or total dietary fiber (50.37  15.61 vs. 54.43  8.23, p=0.499139); however, there 
was a significant increase in the percentage of insoluble dietary fiber (34.42  10.67 vs. 43.79  
5.48, p=0.032455) in the placebo group. The change in percentage of dietary fiber between 
groups was significant for insoluble dietary fiber (p=0.011882187), but was insignificant for 
soluble dietary fiber (p=0.306893128) and total dietary fiber (p=0.68386199).  Change from pre 
to post and significance for the treatment and placebo groups are shown in Table 19. 
Table 19: Percent Dietary Fiber 
Dietary Fiber (%) 
 Treat-
ment Pre 
(mean  
stdev.) 
Treatment 
Post 
(mean  
stdev.) 
Treat-
ment p* 
Placebo Pre 
(mean  
stdev.) 
Placebo Post 
(mean  
stdev.) 
Placebo 
p* 
Delta  
between 
groups 
p* 
Insoluble 
(%) 
 
41.54 
10.72 
39.92  
7.12 
0.687 34.42  
10.67 
43.79  5.48 0.032* 0.012* 
Soluble 
(%) 
 
10.33 
4.86 
12.24  
6.59 
0.502 15.49  
16.46 
10.51  3.81 0.390 0.307 
Total (%) 
 
51.88 
10.39 
53.04  
7.79 
0.779 50.37  
15.61 
54.43  8.23 0.499 0.684 
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SCFA 
 Both concentration (mmol/L) and area percent under the curve were measured for SCFA 
composition of the freeze-dried stool samples in duplicate. No significant change in area percent 
under the curve or concentration was measured from pre to post in the treatment group. No 
significant change in area percent under the curve was seen for the placebo group from pre to 
post; however, a significant change was observed in the placebo group for concentration of 
Isobutyrate (0.51  0.13 vs. 0.40  0.14, p=0.078227) and Isovalerate (0.65  0.16 vs. 0.50  
0.16, p=0.049512). The change in the treatment group compared to the change in the placebo 
group approached significance for butyrate concentration (p=0.054600918). Change from pre to 
post and significance for the treatment and placebo groups are shown in Table 20 and 21. 
Table 20: SCFA: Area Percent Under the Curve 
Area Percent Under the Curve 
SCFA Treatment 
Pre (mean 
 std.) 
Treatment 
Post (mean 
 stdev.) 
Treat-
ment 
p* 
Placebo 
Pre (mean 
 stdev.) 
Placebo 
Post  
(mean  
stdev.) 
Placebo 
p* 
Delta  
between 
groups 
p* 
Acetate 
 
34.668.33 32.80  7.65 0.610 32.42 
5.17 
33.26 5.03 0.716 0.283 
Propionate 
 
21.504.07 20.89  3.88 0.734 24.68  
4.62 
24.96  3.62 0.883 0.525 
Isobutyrate 
 
4.161.77 4.10  1.79 0.941 4.15  1.44 3.92  1.27 0.708 0.744 
Butyrate 
 
25.375.88 28.14  5.06 0.274 25.18  
8.11 
24.41  4.15 0.792 0.174 
Isovalerate 
 
7.78  3.95 7.52  3.76 0.882 7.57  3.19 7.06  2.70 0.704 0.811 
Valerate 
 
5.09  2.55 4.92  2.18 0.875 5.33  1.13 5.20  1.23 0.788 0.945 
Isocaproate 
 
0.19  0.13 0.26  0.23 0.351 0.22  0.19 0.30  0.32 0.462 0.954 
Caproate 
 
1.09  1.13 1.18  0.95 0.852 0.42  0.60 0.86  0.82 0.194 0.327 
Heptanoate 
 
0.17  0.26 0.06  0.10 0.236 0.02  0.07 0.02  0.07 0.997 0.234 
C2+C3+C4 81.538.29 81.83 8.43 0.937 82.29  
5.51 
82.64  5.19 0.886 0.979 
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Table 21: Dietary Fiber: Concentration 
Concentration (mmol/L) 
SCFA Treatment 
Pre 
 (mean  
stdev.) 
 
Treatment 
Post  
(mean  
stdev.) 
Treat-
ment 
p* 
Placebo 
Pre  
(mean  
stdev.) 
Placebo 
Post  
(mean  
stdev.) 
Placebo 
p* 
Delta  
between 
groups 
p* 
Acetate 
 
13.52 7.20 13.89  7.15 0.907 13.04  7.07 10.09 
4.27 
0.273 0.159 
Propionate 
 
4.39  2.30 4.51  2.29 0.913 4.85  2.37 3.69  1.31 0.192 0.170 
Isobutyrate 
 
0.53  0.30 0.57  0.30 0.808 0.51  0.13 0.40  0.14 0.078* 0.124 
Butyrate 
 
3.89 2.29 4.60  2.70 0.533 3.62  2.28 2.70  1.31 0.282 0.055* 
Isovalerate 
 
0.70  0.46 0.74  0.44 0.838 0.65  0.16 0.50  0.16 0.0495* 0.135 
Valerate 
 
0.68  0.45 0.69  0.38 0.960 0.67  0.19 0.55  0.17 0.158 0.221 
Isocaproate 
 
0.36  0.01 0.42  0.16 0.298 0.33  0.12 0.31  0.12 0.750 0.173 
Caproate 
 
0.61  0.21 0.61  0.14 0.958 0.50  0.20 0.52  0.20 0.800 0.856 
Heptanoate 
 
0.68  0.62 0.35  0.48 0.188 0.12  0.39 0.12  0.39 0.997 0.259 
C2+C3+C4 
 
21.8010.78 21.0710.83 0.882 21.5111.06 16.476.59 0.232 0.252 
Total 
SCFA 
25.3711.33 26.3811.89 0.848 24.2911.06 16.476.59 0.224 0.133 
 
  
 64 
CHAPTER 5 
DISCUSSION 
Participants 
 The total sample size for this study was 20, 10 of which were randomized to receive the 
treatment and 10 of which who were randomized to complete the placebo. A relatively small 
sample size with a large number of participant variables, such as differences in age, weight 
classification, lifestyle, and dietary habits could account for small changes in primary outcome 
measures over time. 
Demographics 
 There were no significant differences for age, gender, or ethnicity between the treatment 
and placebo groups. That being said, the was a wide standard deviation in the age of the 
participants in both groups (treatment: 46.80  17.25, placebo: 37.2  16.42). The total cohort 
had a mean age of 42  17.11. Typically, the prevalence of GI symptoms is higher in adults over 
age 50. That being said, several of the participants were recruited from East Tennessee State 
University which may have contributed to a younger participant cohort. Additionally, the 
majority of participants from each group (70%) were female. This supports research that shows 
that the prevalence of constipation and diarrhea is higher in women compared to men. 
Approaching significant differences were seen when looking at the BMI weight classification of 
the treatment and placebo groups. The treatment group had more normal weight (n=6), an equal 
number of overweight (n=3), and a lower number of obese (n=1) participants compared to the 
placebo group (normal weight: n=2, overweight: n=3, and obese: n=5). Since weight 
classification may influence gut fermentation and the gut microbiome, differences in weight 
between groups may affect the results of the study. 
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Assessments 
Food Frequency Questionnaire and Physical Activity 
 Mean daily caloric intake for the total cohort averaged 1543  517.95 calories which is 
typical for most Americans, particularly because the cohort was comprised of 70% females 
(n=14) which typically have lower energy requirements compared to males. Interestingly the 
total cohort had a higher percentage of calories from fat (39.46%) compared to the Dietary 
Guidelines for Americans recommendation of 20-35% of total calories per day.
75
 Calories from 
saturated fat averaged 193.86 (12.56%) which is slightly higher than the recommended intake of 
saturated fat (<10%).
75
 Additionally, fiber intake for total cohort averaged 15.22  7.45 grams 
per day which is below the recommended intake of 20-35 grams per day (varies depending on 
age and sex).75 Dietary intakes higher in total and saturated fat and lower in fiber compared to 
the recommended intake can be a contributing factor to gastrointestinal symptoms in this 
population. 
 Of importance, there was not a significant difference in dietary intake or composition 
between groups at the start of the study. Since diet composition influences gut fermentation and 
the gut microbiome, differences between groups could have skewed the interpretation of results.  
Gastrointestinal Symptoms 
 Out of a possible 91 points, participants in both groups averaged a GIS score of 28.9  
9.65. This indicates that participants had relatively mild gastrointestinal symptoms, but each 
participant met the inclusion criteria of the study in that each person self-reported the presence of 
at least one GIS three or more times per week. Additionally, there was no significant difference 
in starting values between groups which allowed for accurate analysis of ending measures of 
gastrointestinal upset.  
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 A decrease in the presence of total GI symptoms was observed in the treatment group 
from start to finish and a significant decrease was observed for bloating and incidence of loose 
stools in the treatment group. These findings support that combination probiotic, prebiotic, and 
enzyme can improve certain self-reported measures of GIS incidence.   
POMS Assessment 
 Research shows that individuals with GI upset have an impaired quality of life compared 
to individuals without GI upset. The mean results of the POMs questionnaire for this study; 
however, suggests that the starting mood state of all participants (n=20) falls within the normal 
or typical response range. Additionally, a significant change was not observed for any mood state 
over time in the treatment or placebo group. Future research may consider utilizing the POMs 
questionnaire as a method of inclusion. For example, ‘potential research subjects must exhibit an 
elevated or very elevated t-score for total mood disturbance to be included’. This would be a 
better method to evaluate change in mood state as a result of synbiotic supplementation. 
Ultimately, results of this study suggest that individuals with GI upset do not have an altered 
mood state; however, the sample size was very small and a larger research study should be 
conducted to confirm this.  
Blood Analysis 
Immunoglobins 
 A significant reduction in serum IgG levels from start to finish in the treatment group 
could be a serum response to a change in the gut microbiome; however, research is inclusive on 
whether or not the gut microbiota can provoke systemic change to IgG levels.
76 
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Cytokines 
 One potential effect of probiotic intake is a reduction in serum inflammatory markers. 
The results of this study do not indicate that GlutenShield has an effect on IL-2, IL-6, IL-8, or 
TNF-a concentrations. An anomaly was observed in the placebo group, which experienced a 
significant reduction in TNF-a from start to finish.  
Fecal Analysis 
Fiber 
 There are two primary classifications for fiber: insoluble and soluble. Soluble fiber delays 
gastric emptying and increases transit time (slows movement through GI tract). Insoluble fiber 
decreases transit time (speeds up movement through GI tract) and increase fecal bulk. Typically, 
soluble fiber assists with diarrhea while insoluble fiber assists with constipation. Because a 
common claim associated with consuming probiotics is better bowel regularity, we predicted a 
change in fecal dietary fiber concentrations as a result of GlutenShield supplementation. That 
being said, no significant change was observed over time. Fecal dietary fiber concentrations are 
strongly influenced by one’s diet starting and ending values alone are not a good indicator of 
typical fecal fiber concentrations of those with gastrointestinal upset. The change over time, 
however, would be a good measurement of effect. 
SCFA 
 One of the primary hypotheses of this research is that synbiotic (prebiotic and probiotic) 
supplementation would increase fecal SCFA concentrations as an indication of change in total 
gut fermentation. No significant change was seen in the treatment group for any SCFA over time 
and there was no significant change between groups for SCFAs. These results indicate that there 
was no change in fermentation from start to finish. While probiotics may have an indirect effect 
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on SCFA concentration, prebiotics, in particular, have been shown to have the greatest potential 
to increase SCFA production and as a result, affect the microbial composition of the gut. 
Different prebiotic fibers have different effects on SCFA production. That being said, the 
GlutenShield supplement contained several different types of prebiotics (Chitosan 
oligosaccharide, fructooligosaccharides, alfalfa, Emblica officinalis extract, papaya juice 
powder, fulvic acid, and ionic minerals). The GlutenShield supplement may need increased 
amounts of prebiotics or a longer period of supplementation for changes to SCFA concentrations 
to be observed. 
  
 69 
CHAPTER 6 
CONCLUSION 
 Research findings suggest that GlutenShield was well tolerated and perceived to be 
beneficial compared to the placebo. Analysis of the dietary recall shows that the participants had 
higher consumption of total fat and saturated fat while they had lower consumption of dietary 
fiber compared to the recommendations for Americans. Additionally, intake of grains, whole 
grains, fruit, dairy, and beneficial oils fell below the recommended intake. These dietary patterns 
may be a contributing cause of gastrointestinal upset in the population. Results suggest that 
individuals with minor GI upset do not have altered mood states. Additionally, the mood state is 
not affected by GS supplementation. Blood analysis showed unremarkable changes to 
inflammatory markers; however, a significant reduction in IgG levels was observed in the 
treatment group. This reduction could be in response to a change in the gut microbiome; 
however, no definitive statements can be made about this change. Last, no changes to gut 
fermentation (SCFAs) were observed following GS supplementation.  
 There were several limitations to this study. First, the sample size of the study was fairly 
small (n=20). While this is large enough to achieve statistical significance, a larger study may be 
needed to observe true effects of GS supplementation. Second, while it takes a minimum of two 
weeks to observe changes to fermentation and the gut microbiome, increasing the length of study 
to greater than a month may result in a larger improvement in measurements of change. Third, 
demographically, there was a wide range of variability in age, gender, and weight classification 
which can all impact the results of the study. And fourth, while we had planned to include 
microbiome analysis in this study, time constraints of thesis completion resulted in an inability to 
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complete the analysis. Microbiome analysis is currently being completed; however, data is not 
available to make a definitive conclusion on the effects of GlutenShield on the gut microbiome. 
Further research is undeniably needed in the area of prebiotic, probiotic, and enzyme 
supplementation with consideration to the effect on the human gut microbiome, particularly in 
those with gastrointestinal upset. Chronic gastrointestinal upset effects ~33.8% of the population 
and results in significant number of healthcare visits and hospitalizations annually and synbiotics 
may be a novel therapy for GI upset. Additionally, supplemental use of probiotics, prebiotics, 
and enzymes is growing and practitioners must have evidenced-based research to support their 
use in a clinical setting. Larger studies with less demographic variables along with future 
analysis of microbiome data could provide additional insight into the effects of probiotic, 
prebiotic, and enzyme supplementation in individuals with gastrointestinal upset. Additionally, 
studies targeting specific gastrointestinal symptoms (only constipation or only diarrhea) or 
gastrointestinal conditions (i.e. gluten sensitivity) may result in more conclusive data.  
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